netFormulary
 Report : A-Z of formulary items 03/12/2020 17:44:26
[Back]
 
Section Name Details
05.03.01 Abacavir 
  • Available as tablets
  • Life-threatening hypersensitivity reactions have ben reported - characterised by fever or rash and possibly nausea, vomithing, diarrhoea, abdominal pain, dyspnoea, cough, lethargy, malaise, headache and myalgia; less frequently mouth ulceration, oedema, hypotension, sore throat, acute respiratory distress syndrome, anaphylaxis, parasthesia, arthralgia, conjunctivitis, lymphadenopathy, lymphocytopenia and renal failure; rarely myolysis. Laboratory abnormalities may include raised LFTs and CK; symptoms usually appear in the first 6 weeks, but may occur at any time.
  • Discontinue immediately if any symptom of hypersensitivity develops and do not rechallenge (risk of more severe reaction).
05.03.01 Abacavir and Lamivudine Kivexa®
  • Available as tablets
05.03.01 Abacavir with Lamivudine and Dolutegravir Triumeq®
  • Available as tablets
  • If a dose is more than 20 hours late, the missed dose should not be taken an the next dose should be taken at the normal time.
10.01.03 Abatacept Orencia®
  • Available as  SC injection
  • Restricted for use in line with NICE TAs below by rheumatology specialist
08.03.04.02 Abiraterone Zytiga®
11.06 Acetazolamide Diamox SR® RESERVE AGENT
11.08.01 Acetylcysteine 5% with Hypromellose 0.35% Ilube®
05.03.02.01 Aciclovir 
  • Available as:
    • Tablets
    • Dispersible tablets
    • Oral solution
    • Injection
12.03.02 Aciclovir 
  • See section 5 infection
11.03.03 Aciclovir 3% eye ointment 
03.01.02 Aclidinium Eklira Genuair®
  • Available as 322mcg/dose inhaler ££/60 dose
03.01.04 Aclidinium bromide with Formoterol Duaklir Genuair®
  • Available as Duaklir 340mcg/12mcg/dose Genuair ££/60 dose
01.05.03 Adalimumab Hyrimoz® Humira®
  • Available as injection £££££
10.01.03 Adalimumab Hyrimoz®
  • Available as  SC injection
  • Restricted for use in line with NICE TAs below by rheumatology specialist
  • Biosimilar Hyrimoz<sup>®</sup> is new first line agent for GEH patients

 

 

02.03.02 Adenosine 
  • Available as injection 6mg/2mL ££/6 ampoules
02.07.03 Adrenaline / Epinephrine 
  • Available as injection
03.04.03 Adrenaline / epinephrine 
08.01.06 Aflibercept Zaltrap®
06.06.02 Alendronic Acid 
06.06.02 Alendronic acid effervescent tablets Binosto®
  • For use in patients who are unable to swallow tablets where Alendronic acid is the appropriate treatment choice
09.06.04 Alfacalcidol One-Alpha®
  • Available as capsules
  • To be prescribed on advice of specialist only
15.01.04.03 Alfentanil 
  • Available as injection 1mg/2mL & 5mg/10mL
07.04.01 Alfuzosin Xatral®
10.01.04 Allopurinol 
  • Available as tablets
07.04.05 Alprostadil Caverject® Viridal® MUSE®
02.10.02 Alteplase 
  • Available as injection 10mg & 50mg ££££/vial (both strengths)
05.01.04 Amikacin 
  • Available as injection
02.02.03 Amiloride 
  • Available as:
    • Tablets £
    • Oral solution (expensive compared to tablets) ££/150mL
  • Tablets will disperse in water if needed (not licensed)
03.01.03 Aminophylline  
  • Available as 250mg/10mL injection ££/10 ampoules
03.01.03 Aminophylline Phyllocontin Continus®
  • Available as 225mg MR tablets £/56 tablets
02.03.02 Amiodarone 
  • Available as:
    • Tablets 100mg & 200mg £/28 tablets (both strengths)
    • Injection 150mg/3mL ££/10 ampoules
    • Injection 300mg/10mL (cardiac boxes) ££/pre-filled syringe
04.03.01 Amitriptyline 
  • Available as:
    • 10mg, 25mg & 100mg tablets £/28 all strengths
    • Oral solution 25mg/5mL ££/150mL
  • Please note that the dose used for depressive illness is usually higher than dose used for neuropathic pain/migraine prophylaxis/abdominal discomfort.
  • Patients should be encouraged to persist with treatment as some tolerance to side-effects seems to develop. Tehy are reduced if low doses are given initially and then gradually increased, but this must be balanced against the need to obtain a full therapeutic effect as soon as possible.
04.07.03 Amitriptyline 
04.07.04.02 Amitriptyline 
02.06.02 Amlodipine 
  • Available as tablets 5mg & 10mg £ (both strengths)
05.01.01.03 Amoxicillin 
  • Available as :
    • Tablets
    • Injection
    • Oral solution
05.02.03 Amphotericin AmBisome®
  • Available as injection
08.03.04.01 Anastrozole Arimidex®
11.04.02 Antazoline 0.5% with Xylometazoline 0.05% eye drops Otrivine-Antistin® Allergic conjunctivitis (seasonal)

Maximum 7 days treatment

Can be sold to the public for the treatment of allergic conjunctivitis
02.08.01 Anticoagulant Citrate Dextrose Solution ACD-A

ACD-A is in a pre-made infusion bag and therefore does not have to be prepared in comparison to Heparin.

Reduced cost in comparison to Heparin Saline

Reduces human error as the product does not have to be prepared before use.

Reduces risk of needlestick injury

Can be used in patients where Heparin in contraindicated

Reduced risk of bleeding

Can be used in patients where systemic anticoagulationis contra-indicated

 

14.05.03 Anti-D (Rh0) Immunoglobulin Rhophylac®
  • Availabe as Rhophylac 1500units/2mL solution for injection pre-filled syringe
02.08.02 Apixaban Eliquis®
  • Available as tablets 2.5mg £££/60 tablets & 5mg ££/28 tablets
  • Indications
    • Stroke prevention in AF (SIDC to be completed and faxed to GP surgery)
    • Treatment and prevention of thromboembolic events (SIDC to be completed and faxed to GP surgery)
11.08.02 Apraclonidine 1% eye drops Iopidine®
  • PRE-OP ONLY
04.06 Aprepitant Emend®
  • Available as capsule 125mg/80mg £££/3 capsule pack
13.02.01 Aquamax Cream® 
  • £/500g
  • Alternative to aqueous cream, can be used as a wash
13.02.01.01 Aquamax Wash® 
  • £/250g
  • Aquamax cream can also be used as a soap substitute
  • Dermatology only
09.06.03 Ascorbic Acid 
  • Available as tablets
02.09 Aspirin  
  • Available as:
    • Dispersable tablets 75mg (preferred) £/28
    • Enteric coated 75mg £/56
    • Suppositories 150mg ££/10
05.03.01 Atazanavir Reyataz®
  • Available as capsules
  • Mild to moderate rash occurs commonly, usually within the first 3 weeks of therapy. Severe rash occurs less frequently and may be accompanied by systemic symptoms. Discontinue if severe rash develops.
05.03.01 Atazanavir with cobicistat Evotaz®
  • Available as tablets
02.04 Atenolol 
  • Available as:
    • Tablets 25mg, 50mg & 100mg £/28 tablets (all strengths)
    • Oral solution 25mg/5mL ££/300mL
    • Injection 5mg/10mL ££/10 ampoules
08.01.06 Atezolizumab Tecentriq®
02.12 Atorvastatin 
  • Available as tablets 10mg,20mg,40mg,80mg £/28 all strengths
15.01.05 Atracurium Besilate Tracrium®
  • Available as injection
15.01.03 Atropine 
  • Available as:
    • 600micrograms/1mL
    • 1mg/5mL (for cardiac boxes)
11.05 Atropine Sulphate 1% eye drops  Indications: cycloplegia & anterior uveitis
13.02.01 Aveeno Cream 
  • £/100mL & ££/500mL
  • For dermatology outpatients only as per ACBS criteria
08.01.06 Axitinib Inlyta®
08.01.03 Azacitidine Vidaza®
01.05.03 Azathioprine 
  • Available as 25mg & 50mg tablets £ (both strengths and all pack sizes)
08.02.01 Azathioprine 
10.01.03 Azathioprine 
  • Available as tablets
12.02.01 Azelastine Hydrochloride Rhinolast®
  • Available as 0.1% nasal spray
05.01.05 Azithromycin 
  • Available as:
    • Tablets
    • Capsules
    • Oral solution
  • SPECIALIST INITIATED FOR PROPHYLAXIS IN EXACERBATIONS OF COPD

 

10.02.02 Baclofen 
  • Available as:
    • Tablets
    • Oral solution
13.02.01 Balneum Cream 
  • ££/500g
  • Contains urea
  • Dermatology only
13.02.01 Balneum Plus Cream 
  • £/100g & ££/500g
  • Contains urea
  • Dermatology only
08.02.04 BCG bladder instillation OncoTICE®
03.02 Beclometasone and formoterol Fostair®pMDI Fostair® NEXThaler
  • Available as:
    • pMDI 100/6 & 200/6 ££/120 dose 
    • DPI (NEXThaler) 100/6 & 200/6 ££/120 dose
03.02 Beclometasone dipropionate Qvar®
  • Available as pMDI 50 & 100 ££/200 dose
03.02 Beclometasone dipropionate Clenil Modulite®
  • Available as pMDI 50 £/200 dose, 100 ££/200 dose, 200 ££/200 dose & 250 ££/200 dose
03.01.04 Beclometasone/formoterol/glycopyrronium Trimbow®
  • Available as pMDI ££/120 dose
12.02.01 Beclomethasone Dipropionate 
  • Available as 50mcg/dose nasal spray 120 dose
08.01.01 Bendamustine 

CDF for relapsed low grade lymphoma and relapsed multiple myeloma (Bendamustine is not licensed in these indications)

02.02.01 Bendroflumethiazide 
  • Available as tablets £
  • No longer recomended as first line for hypertension but in those patients who are currently stable with good blood pressure control it is ok to continue treatment
12.03.01 Benzydamine Difflam®
  • Available as:
    • 0.15% spray
    • 0.15% oral rinse solution
05.01.01.01 Benzylpenicillin 
  • Also known as Penicillin G
  • Available injection
05.01.01.01 Benzylpenicillin Benzathine IM injection 
  • Available as 2.4 Mega Unit injection
  • For GUM clinic only for the treatment of early syphilis and late latent syphilis
04.06 Betahistine Dihydrochloride 
  • Available as:
    • Tablets 8mg £/84
12.03.01 Betamethasone 
  • Available as 500mcg soluble tablet
  • Tablets to be dissolved in 20mL of water and rinsed around the mouth; not to be swallowed
11.04.01 Betamethasone 0.1% eye drops 
12.01.01 Betamethasone 0.1% with Neomycin 0.5% Betnesol N®
  • Available as ear/eye/nose drops 10mL
11.04.01 Betamethasone 0.1% with Neomycin 0.5% eye drops Betnesol N® Betamethasone with neomycin eye-drops are less suitable for prescribing
12.01.01 Betamethasone sodium phosphate Vistamethasone®
  • Available as ear/eye/nose drops 10mL
12.02.01 Betamethasone sodium phosphate Vistamethasone®
  • Available as 0.1% ear/eye/nose drops 10mL
11.06 Betaxolol 0.25% & 0.5% eye drops Betoptic® STEP TWO: Beta-blockers
08.01.06 Bevacizumab Avastin®

CDF for first line treatment of recurrent or metastatic cervical cancer in combination with chemotherapy, third line treatment of glioma in childhood and first line treatment of advanced epithelial ovarian, fallopian tube or primary peritoneal cancer.

08.03.04.02 Bicalutamide 
05.03.01 Bictegravir with Emtricitabine and Tenofovir Alafenamide Biktarvy ®
  • Available as tablets
  • Manufacturer advises if a missed dose is more than 18 hours late, the missed dose should not be taken and the next dose should be taken at the normal time
11.06 Bimatoprost 300mcg/ml eye drops Lumigan® STEP ONE: Prostaglandin analogues
11.06 Bimatoprost with Timolol Ganfort® STEP THREE: Prostaglandin combination preparations (or STEP TWO at the discretion of the physician)
06.01.01.02 Biphasic Insulin Aspart NovoMix® 30
  • Intermediate acting
06.01.01.02 Biphasic Insulin Lispro Humalog® Mix25 Humalog® Mix50
  • Intermediate acting
06.01.01.02 Biphasic Isophane Insulin Humulin® M3
  • Intermediate acting
01.06.02 Bisacodyl 
  • Avaiable as:
    • Tablets ££
    • Suppositories £/12 suppositories
  • Time to effect is approximately 10-12 hours for tablets and 20-60 minutes for suppositories
02.04 Bisoprolol 
  • Available as tablets 1.25mg, 2.5mg, 3.75mg, 5mg & 10mg £/28 tablets
08.01.02 Bleomycin 
06.01.06 Blood glucose testing strips (inpatient use) Freestyle Optium®, Freestyle Precision Pro®
06.01.06 Blood glucose testing strips (outpatient use) Accu-check® Performa, GlucoMen® Areo
06.01.06 Blood ketones testing strips (inpatient use) Freestyle Optium®, Freestyle Precision Pro®
06.01.06 Blood ketones testing strips (outpatient use) beta ketone, GlucoMen® Areo
14.04 Boostrix-IPV 
  • diphtheria/tetanus/5-component acellular pertussis/inactivated polio vaccine (DTaP/IPV)
  • Boostrix- IPV is the vaccine offered to pregnant women to protect their new born from pertussis
08.01.06 Bortezomib Velcade®

CDF for the treatment of bortezomib naive relapsed multiple myeloma

08.01.06 Bosutinib Bosulif®
08.01.06 Brentuximab vedotin Adcetris®

CDF for relapsed or refractory CD30+ Hodgkin's lymphona after at least 2 previous therapies and cannot have autologous stem cell translplant or multi-agent chemotherapy

BlueTeq for relapsed or refractory CD30+ Hodgkin's lymphona after autologous stem cell transplant and for relapsed or refractory systemic large cell lymphoma

11.06 Brimonidine Tartrate 0.2% eye drops Alphagan® STEP FIVE: Sympathomimetics
11.06 Brimonidine Tartrate 0.2% with Timolol 0.5% Combigan® STEP SIX: Carbonic anhydrase inhibitor or Sympathomimetic combination preparations
11.06 Brinzolamide 10mg/ml eye drops Azopt® STEP FOUR: Carbonic anhydrase inhibitors
11.06 Brinzolamide with Timolol Azarga®

STEP SIX: Carbonic anhydrase inhibitor or Sympathomimetic combination preparations 

**Prescriptions should be challenged to ensure that patients have previously received first line treatment with Cosopt before moving onto Azarga**

04.08.01 Brivaracetam Briviact
  • Add on therapy for patients refractory to other drugs
01.05.02 Budesonide Cortiment®
  • Available as MR tablets £££/30 tablets
  • Licensed for induction of remission of mild to moderate active ulcerative colitis
  • Restricted to those who have failed to obtain control of their ulcerative colitis using salicylates; but are unable to tolerate or unwilling to take high dose steroids
  • Until approved at APC we will fulfil the whole 8 week prescription from GEH
01.05.02 Budesonide Budenofalk® Entocort®
  • Available as capsules £££/100 capsules (both brands)
  • Licensed for mild to moderate Crohn's disease affecting the ileum or ascending colon
  • Budenofalk® capsules - 3mg 3 times a day for up to 8 weeks, reduce dose for the last 2 weeks of treatment
  • Entocort® capsules - 9mg once daily for up to 8 weeks; reduce dose for the last 2-4 weeks of treatment, to be taken in the morning (dispense in origional container, contains desicant)
03.02 Budesonide Pulmicort®
12.02.01 Budesonide Rhinocort Aqua®
  • Available as 64mcg/dose nasal spray 120 dose
03.02 Budesonide and formoterol Symbicort®
  • Available as turbohaler 100/6, 200/6 & 400/12 ££/device
02.02.02 Bumetanide 
  • Available as:
    • Tablet 1mg £ & 5mg ££
    • Oral solution (extremely expensive) ££££/150mL bottle
  • Tablets disperse in water if needed (not licensed)
15.02 Bupivacaine hydrochloride Marcain®
  • Available as 0.25% & 0.5% injection
15.02 Bupivacaine Hydrochloride with Glucose Marcain Heavy®
  • Available as injection
15.02 Bupivacaine with Fentanyl 
  • Available as injection (bupivacaine 0.125% with fentanyl 2mcg/mL 240mL bag)
04.07.02 Buprenorphine patch Reletrans® Buplast®
04.07.02 Buprenorphine sublingual tablets Temegesic®
08.01.06 Cabazitaxel Jevtana®
06.07.01 Cabergoline 
08.01.06 Cabozantinib Cometriq® Cabometyx®
09.05.01.01 Calcium Chloride 
  • Available as 10% injection
09.05.01.01 Calcium Gluconate 
  • Available as 10% injection
09.05.01.01 Calcium Salts Adcal®
  • Available as chewable tablets
09.05.01.01 Calcium Salts Calcichew®
  • Available as chewable tablets
06.01.02.03 Canagliflozin Invokana®
02.05.05.02 Candesartan 
  • Available as tablets 2mg (7), 4mg (28) & 8mg (28) £ all strengths
08.01.03 Capecitabine Xeloda®
10.03.02 Capsaicin Zacin®
  • Available as cream
10.03.02 Capsaicin Qutenza®
  • Available as a medicated plaster (pain clinic)
04.07.03 Capsaicin 0.075% cream Axsain®

Painful diabetic neruopathy

04.07.03 Capsaicin 0.075% cream Axsain®
04.07.03 Capsaicin plaster Qutenza®

Peripheral neuropathic pain in non-diabetic patients

04.07.03 Carbamazepine 
04.08.01 Carbamazepine 
  • MHRA advises prescribing by brand to avoid loss of seizure control by switching brands
06.02.02 Carbimazole 

NEUTROPENIA AND AGRANULOCYTOSIS

Doctors are reminded of the importance of recongnising bone marrow suppression induced by carbimazole and the need to stop treatment promptly.

  • Patient should be asked to report symptoms and signs suggestive of infection, especially sore throat.
  • A white blood cell count should be performed if there is any clinical evidence of infection.
  • Carbimazole should be stopped promptly if there is clinical or laboratory evidence of neutropenia.
03.07 Carbocisteine 
  • Available as:
    • 375mg capsules £/120
    • 250mg/5mL oral solution ££/300mL
11.08.01 Carbomer ’980’ 0.2% eye gel Viscotears®
08.01.06 Carboplatin 
07.01.01 Carboprost Hemabate®
11.08.01 Carmellose 0.5% & 1% eye drops Celluvisc®
11.06 Carteolol 1% & 2% eye drops Teoptic® STEP TWO: Beta-blockers
02.04 Carvedilol 
  • Available as tablets 3.125mg, 12.5mg & 25mg £/28 tablets
05.02.04 Caspofungin Cancidas®
  • Available as injection
05.01.02.01 Cefalexin 
  • Available as:
    • Capsules
    • Oral solution
05.01.02.01 Cefotaxime 
  • Available as injection
  • Used in the treatment of Spontaneous Bacterial Peritonitis in Cirrhosis as per trust guidelines
05.01.02.01 Ceftriaxone 
  • Available as injection
11.03.01 Cefuroxime Aprokam® Intracameral injection
  • Prophylaxis of endophthalmitis after cateract surgery
10.01.01 Celecoxib Celebrex®
  • Available as capsules
10.01.03 Certolizumab Pegol Cimzia®
  • Available as  SC injection
  • Restricted for use in line with NICE TAs below by rheumatology specialist
03.04.01 Cetirizine 
  • Available as:
    • 10mg tablet £/30
    • 5mg/5mL oral solution £/200mL
13.02.01 Cetraben Cream® 
  • ££/500g
  • Dermatology advised only
13.02.01 Cetraben Lotion® 
  • £/500mL
  • May be used as an alternative to Aveeno Cream and Lotion
13.02.01 Cetraben Ointment® 
  • £/450g
  • Dermatology advised only
08.01.06 Cetuximab Erbitux®
08.01.01 Chlorambucil 
05.01.07 Chloramphenicol 
  • Available at injection
11.03.01 Chloramphenicol 0.5% eye drops and 1% ointment 
04.01.02 Chlordiazepoxide 
12.02.03 Chlorhexidine Hydrochloride 0.1%, Neomycin Suphate 0.5% Naseptin®
  • Available as nasal cream 15g
  • May contain Arachis (peanut) oil, therefore NOT SUITABLE FOR PATIENTS WITH A PEANUT ALLERGY
12.03.04 Chlorhexidine mouthwash 
  • Available as  0.2% mouthwash 300mL
15.02 Chloroprocaine Hydrochloride 10mg/ml Ampres ®

Ampoules

02.02.01 Chlorothiazide 
  • Available as 250mg/5ml suspension - restircted for paediatric use only £££/237mL bottle (unlicensed special)
03.04.01 Chlorphenamine 
  • Available as:
    • 10mg/1mL injection ££/5 ampoules
    • 4mg tablets £/28
    • 2mg/5mL oral solution £/150mL
12.03.01 Choline Salicylate Bonjela® Adult
  • Available as oral gel 15g
  • The CHM has advised that topical oral pain relief products containing salicylate salts should not be used in children under 16 years, as a cautionary measure due to the theoretical risk of Reye's syndrome
01.05.03 Ciclosporin 
  • Available as capsules £-££/30 capsules (depending on strength)
  • MHRA specify that ciclosporin must be prescribed and dispensed by brand as bioavailability differences exist between brands - NEORAL is the preferred brand at GEH
  • Specialist only for Ulcerative colitis (shared care for other indications)
10.01.03 Ciclosporin 
  • Available as capsules
09.05.01.02 Cinacalcet Mimpara®
  • Available as tablets
04.06 Cinnarizine 
  • Available as:
    • Tablets ££/84
05.01.12 Ciprofloxacin 
  • Available as:
    • Tablets
    • Oral solution
    • Injection
  • Oral solution should not be used for administration via enteral feeding tubes as the beads can cause blockages. Instead disperse tablets, also stop the feed for one hour prior and post administration otherwise absorption of ciprofloxacin is markedly reduced.
12.01.01 Ciprofloxacin 
  • Available as 0.3% eye drops 5mL
  • Please note that ciprofloxacin eye drops are ok for use in the ear
11.03.01 Ciprofloxacin 0.3% eye drops 
08.01.06 Cisplatin 
04.03.03 Citalopram 
  • Available as
    • Tablets 10mg & 20mg £/28
    • Oral drops 40mg/mL £/15mL
  • Maximum 20mg/day in elderly patients.
  • 4 oral drops (8mg) is equivalent in therapeutic effect to 10mg tablet.
08.01.03 Cladribine 
05.01.05 Clarithromycin 
  • Available as:
    • Tablets
    • Injection
    • Oral solution
05.01.06 Clindamycin 
  • Available as:
    • Tablets
    • Injection
07.02.02 Clindamycin Dalacin®
04.08.01 Clobazam 
06.05.01 Clomifene Citrate 
  • The CSM has recommended that clomifene should not normally be used for longer than 6 cycles (possibly increased risk of ovarian cancer).
04.08.01 Clonazepam 
02.09 Clopidogrel 
  • Available as tablets £/28
07.02.02 Clotrimazole 
12.01.01 Clotrimazole Canesten®
  • Available as 1% solution
  • Please note this is called canesten solution rather than ear drops
02.02.04 Co-amilofruse 
  • Available as tablets 2.5/20 & 5/40 ££ (both strengths)
05.01.01.03 Co-Amoxiclav 
  • Available as:
    • Tablets
    • Injection
    • Oral solution
04.09.01 Co-Beneldopa Madopar® Madopar CR®
04.09.01 Co-Careldopa Sinemet® Sinemet Plus® Half Sinemet CR ® Sinemet CR®
04.09.01 Co-Careldopa and Entacapone Stalevo®
03.09.01 Codeine Phosphate 
  • Available as 15mg/5mL linctus £/200mL
04.07.02 Codeine Phosphate 
10.01.04 Colchicine 
  • Available as tablets
09.06.04 Colecalciferol 
  • Available as:
    • 800 units capsules
    • 20000 units capsules
    • 50000 units capsules
    • 3000 units/mL oral solution
    • 25000 units/mL oral solution
09.06.04 Colecalciferol and Calcium Carbonate Adcal-D3®
  • Adcal D3 chewable tablet contains 1.5g calcium carbonate and 400 units colecalciferol
  • Adcal D3 caplets contains 750mg calcium carbonate and 200 units colecalciferol
  • Available as:
    • Adcal D3 chewable tables 1 tablet BD
    • Adcal D3 caplets 2 caplets BD
09.06.04 Colecalciferol and Calcium Carbonate Calcichew-D3®
  • Calcichew D3 contains 2.5g calcium carbonate and 800 units colecalciferol
  • Available as chewable tablet
09.06.04 Colecalciferol and Calcium Carbonate Calcichew-D3® Forte
  • Calcichew D3 Forte contains 1.25g calcium carbonate and 400 units colecalciferol
09.06.04 Colecalciferol and Calcium Carbonate Cacit D3®
  • Cacit D3 contains 1.25g calcium carbonate and 440 units colecalciferol
  • Available as effervescent granules for patients with swallowing difficulties/enteral feeding tubes
01.09.02 Colestipol Colestid®
  • for use whilst supply problem with Colestyramine
01.09.02 Colestyramine 
  • Available as sachets ££/50 sachets
  • The contents of each sachet should be mixed with 150mL of water or other suitable liquid such as fruit juice, skimmed milk, thin soups, and pulpy fruits with a high moisture content. Other drugs should be taken at least 1 hour before or 4-6 hours after colestyramine to reduce possible interference with absorption
02.12 Colestyramine Questran® Light
  • Available as sugar free sachets ££/50
05.01.07 Colistimethate for nebulisation Colomycin®
  • Available as injection (Colomycin® brand licensed for nebulisation)
09.02.02.01 Compound Sodium Lactate Intravenous Infusion 
  • Available as
    • Compound Sodium Lactate 1000ml bag
05.01.08 Co-trimoxazole 
  • Available as:
    • Tablets
    • Oral solution
    • Injection
08.01.06 Crizotinib Xalkori®

CDF for NICE TA529 if the conditions in the managed access agreement are followed.

BlueTeq for NICE TA406 and NICE TA422

09.01.02 Cyanocobalamin 
  • Available as tablets
04.06 Cyclizine 
  • Available as:
    • Tablets 50mg ££/100
    • Injection 50mg/1mL ££/10 ampoules
11.05 Cyclopentolate Hydrochloride 0.5% (children) & 1% (adults) eye drops  Indication: cycloplegia and anterior uveitis
08.01.01 Cyclophosphamide 
06.04.02 Cyproterone Acetate 
08.03.04.02 Cyproterone Acetate 
08.01.03 Cytarabine 
02.08.02 Dabigatran Pradaxa®
  • Available as capsules 110mg £££/60 capsules & 150mg £££/60 capsules
  • Indications
    • Stroke prevention in AF (SIDC to be completed and faxed to GP surgery)
    • Treatment and prevention of thromboembolic events (SIDC to be completed and faxed to GP surgery)
    • Prophylaxis of VTE post hip and knee replacement surgery (complete course to be supplied by hospital)
08.01.01 Dacarbazine 
05.03.03.02 Daclatasvir Daklinza®
  • Available as tablets
  • If a dose is more than 20 hours late, the missed dose shold not be taken an the next dose should be taken at normal time.
  • May affect performance of skilled tasks (e.g. driving).
02.08.01 Danaparoid 
15.01.08 Dantrolene Sodium Dantrium Intravenous®
  • Available as injection
06.01.02.03 Dapagliflozin Forxiga▼®
07.04.06 Dapoxetine Priligy®
05.01.07 Daptomycin Cubicin®
  • Available as injection
  • To be used only on microbiology advice
08.01.06 Daratumumab Darzalex®
09.01.03 Darbepoetin Alfa Aranesp®
  • Available as injection
05.03.01 Darunavir Prezista®
  • Available as tablets
  • Mild to moderate rash occurs commonly, usually within the first 4 weeks of therapy and resolvees without stopping treatment. Severe skin rash (including Stevens-Johnson symtrom and toxic epidermal necrolysis) occurs less frequently and may be accompanied by fever, malaise, arthralgia, myalgia, oral lesions, conjunctivitis, hepatitis or eosinophilia; treatment should be stopped if this develops.
  • If a dose is more than 6 hours late on the twice daily regimen (or more than 12 hours late on the once daily regimen), the missed dose should not be taken and the next dose should be taken at the normal time.
05.03.01 Darunavir with cobicistat Rezolsta®
  • Available as tablets
05.03.01 Darunavir with Cobicistat, Emtricitabine and Tenofovir Alafenamide Symtuza ®
  • Available in tablets
  • Pharmacokinetic data show mean exposure of Darunavir boosted with Cobicistat (available in combination in Rezolasta and Symtuza) to be lower during 6-12 weeks postpartum. Low Darunavir exposure may be associated with an increased risk of HIV-1 transmission to the unborn child.
05.03.03.02 Dasabuvir Exviera®
  • Available as tablets
08.01.06 Dasatinib Sprycel®

BlueTeq for NICE TA426

09.01.03 Deferasirox Exjade ®

Once a day treatement as opposed to Desferal

Can be used for patients who become intolerant to Desferal as second line treatment for Iron Chelation

Haematology patients only

08.03.04.02 Degarelix Firmagon®
05.01.03 Demeclocycline 

Used in the treatment of hyponatraemia - as advised by endocrinology

06.05.02 Demeclocycline 
06.06.02 Denosumab XGEVA®
13.02.01 Dermol 500 Lotion® 
  • ££/500mL
  • Contains antimicrobial, should only be used short term for infected/active eczema
  • Can be used as a wash (use Aquamax where long term wash required)
  • Dermatology only
13.02.01 Dermol Cream® 
  • £/100g & ££/500g
  • Contains antimicrobial, should only be used short term for infected/active eczema
  • Dermatology only
09.01.03 Desferrioxamine mesilate 
  • Available as injection
06.05.02 Desmopressin 
  • Available as tablets, solution for injection, nasal spray and oral lyophilisate
06.03.02 Dexamethasone 
11.04.01 Dexamethasone 0.1% eye drops Maxidex® Maxidex® not licensed for use in children under 2 years
12.01.01 Dexamethasone with Antibacterial Otomize®
  • Dexamethasone with glacial acetic acid and neomycin sulfate
  • Available as ear spray 5mL
12.01.01 Dexamethasone with Antibacterial Sofradex®
  • Dexamethasone with framycetin sulfate and gramicidin
11.04.01 Dexamethasone with framycetin sulfate and gramicidin eye drops Sofradex® Sofradex® is less suitable for prescribing
11.04.01 Dexamethasone with hypromellose, neomycin and polymyxin B sulfate Maxitrol® Dexamethasone with neomycin and polymyxin B sulfate is less suitable for prescribing
Available as eye drops and eye ointment
11.04.01 Dexamethasone with tobramycin eye drops Tobradex® Dexamethasone with tobramycin eye-drops are less suitable for prescribing
15.01.04.04 Dexmedetomidine  Dexdor®
  • Available as injection 200mcg/2mL & 400mcg/2mL
  • Dexmedetomidine should only be administered by, or under the direct supervision of, personnel experienced in its use, with adequate training in anaesthesia and airway management.
08.01 Dexrazoxane 
04.07.02 Diamorphine 
04.01.02 Diazepam 
  • Available as :
    • 2mg, 5mg & 10mg tablets £/28 all strengths
    • 2mg/5mL oral solution ££/100mL
    • 10mg/2mL injection ££/10 ampoules
    • 5mg/2.5mL & 10mg/2.5mL rectal tubes ££/5 tubes both strengths
04.08.02 Diazepam  IV diazepam is effective but carries a high risk of thrombophlebitis (reduced by using an emulsion formulation). Absorption of diazepam from intramuscular injection or from suppositories is too slow for treatment of status epilepticus.
10.02.02 Diazepam 
  • Available as:
    • Tablets
    • Oral solution
15.01.04.01 Diazepam 
  • Available as:
    • Tablets 2mg & 10mg
    • Injection 10mg/2mL
    • Oral solution 2mg/5mL
  • See Chapter 4 for rectal use in epilepsy
10.01.01 Diclofenac 
  • Available as:
    • Tablets
    • Suppositories
  • Due to the small cardiac risks associated with diclofenac, ibuprofen (up to 1200mg/day) or naproxen should be considered instead
  • Please note that APC have said diclofenac is not suitable for repeat prescribing, will be issued for short term use only
11.08.02 Diclofenac Sodium 0.1% eye drops Voltarol® Ophtha multidose
  • PRE-OP ONLY
08.03.01 Diethylstilbestrol 
02.01.01 Digoxin 
  • Available as:
    • Tablet £
    • Elixir ££/60mL
    • Injection £/5 vials
  • Bioavailabilities are approximately: injection 100%, elixir 75%, tablet 63%
  • ONE 62.5mcg tablet is ~ equivalent to 50mcg (1mL) elixir
02.01.01 Digoxin specific antibody fragments Digifab®
  • Available as injection £££££
  • Very rarely needed and extremely expensive (~£1000 per vial and up to 30 vials may be needed!), discuss with the National Poisons Information Service 0344 892 0111
  • DigiFab® replaced Digibind® (Dec 2011)
04.07.02 Dihydrocodeine 
  • To be used only if codeine not tolerated
02.06.02 Diltiazem  
  • Available as tablets/capsules
  • Once daily preparations are preferred
  • Prescribers should specify the brand to be dispensed, different versions of modified release preparations containing more than 60mg diltiazem may not have the same clinical effect - contact pharmacy for most cost-effective brand
01.07.04 Diltiazem Cream 2% 
  • Available as cream ££/30g
07.01.01 Dinoprostone Prostin E2®
  • Available at vaginal tablet or vaginal gel
02.09 Dipyridamole 
  • Available as 200mg MR capsules ££/60
06.06.02 Disodium Pamidronate 
02.07.01 Dobutamine 
  • Available as injection 250mg/20mL ££/5 vials
08.01.06 Docetaxel 
01.06.03 Docusate Sodium 
  • Available as:
    • Caspules ££/100 capsules
    • Syrup ££/300mL bottle
  • Time to effect approximately 1-2 days
05.03.01 Dolutegravir Tivicay®

Dolutegravir is a HIV-integrase inhibitor

  • Available as tablets
  • Hypersensitivity reactions (including severe rash, or rash accompanied by fever, malaise, arthralgia, myalgia, blistering, oral lesions, conjunctivitis, angiodema, eosinophilia or raised LFTs) reported uncommonly. Discontinue immediately if any sign or symptoms of hypersensitivity reactions develop.
  • If a dose is more than 20 hours late on the once daily regimen or more than 8 hours late on the twice daily regimen, the missed dose should not be taken and the next dose should be taken at the normal time.
04.06 Domperidone 
  • Available as:
    • Tablets 10mg £/30 & £/100
    • Oral solution 5mg/5mL ££/200mL
04.11 Donepezil 
02.07.01 Dopamine 
  • Available as injection
11.06 Dorzolomide 2% with Timolol 0.5% Cosopt® STEP SIX: Carbonic anhydrase inhibitor or Sympathomimetic combination preparations
11.06 Dorzolomide 2% eye drops Trusopt® STEP FOUR: Carbonic anhydrase inhibitors
13.02.01 Doublebase gel 
  • £/100g & ££/500g
  • Dermatology only
03.05.01 Doxapram Dopram®
  • Available as 100mg/5mL injection ££££/5 ampoules
15.01.07 Doxapram Dopram®
  • Available as injection
02.05.04 Doxazosin 
  • Available as:
    • tablets 1mg, 2mg & 4mg £/28 tablets
    • MR tablets 4mg ££/28 tablets
  • Doxazosin may be used as a 4th line option in the management of hypertension when control has not been achieved with other agents
  • MR tablets should be reserved for initiation by a specialist in patients with difficult to treat hypertension who are unable to tolerate immediate release tablets
08.01.02 Doxorubicin Hydrochloride 
05.01.03 Doxycycline 
  • Available as:
    • Capsules
    • Dispersibele tablet
02.03.02 Dronedarone 
  • Available as tablets £££
  • Dronedarone should be initiated by a sepcialist in line with NICE TA197, after the patient is stabilised on treatment, prescribing may be continued in primary care under shared care arrangements
  • Due to its safety profile, dronedarone should only be prescribed after alternative treatment options have been considered
03.01.05 Drug Delivery Device AeroChamber Plus® Volumatic®
  • Spacer devices remove the need for coordination between acutation of a pMDI and inhalation. The spacer device reduces the velocity of the aerosol and subsequent impaction on the oropharynx and allows more time for evaporation of the propellant so that a larger proportion of the particles can be inhaled and deposited in the lungs.
  • £/device & ££/device with mask
03.01.05 Drug Delivery Device Haleraid®
  • Available as 120 and 200 dose £/device
  • For patients with dexterity problems
06.01.02.03 Dulaglutide 
04.03.04 Duloxetine 
  • Available as capsules 20mg, 30mg & 60mg £/28 all strengths
04.07.03 Duloxetine 
07.04.02 Duloxetine Yentreve®
  • For stress incontinence in women
06.04.02 Dutasteride 
07.04.01 Dutasteride and Tamsulosin Combodart®
13.02.01 E45 Cream 
  • £/100g & ££/500g
02.08.02 Edoxaban Lixiana®
  • Available as tablets 30mg ££/28 tablets & 60mg ££/28 tablets
  • Indications
    • Stroke prevention in AF (SIDC to be completed and faxed to GP surgery)
    • Treatment and prevention of thromboembolic events (SIDC to be completed and faxed to GP surgery)
05.03.01 Efavirenz Sustiva®
  • Available as tablets
  • Rash usually in the first 2 weeks, is the most common side-effect; discontinue if sever rash with blistering, desquamation, mucosal involvement or fever; if rash mild or moderate, may continue withoug interruption - usually resolves within 1 month.
  • Administration at bedtime especially in the first 2-4 weeks reduces CNS effeccts.
  • Patients or their carers should be advised to seek immediate medical attention if symptoms such as sever depression, psychosis or suicidal ideation occur.
05.03.03.02 Elbasvir with grazoprevir Zepatier®
  • Available as tablets
  • Patients and their carers should consult a healthcare professional if signs and symptoms of hepatic dysfunction occur (including fatigue, weakness, lack of appetite, nausea and vomiting, jaundice or discoloured faeces).
  • If vomiting occurs within 4 hours of a dose, an additional dose should be taken.
  • If a dose is more than 16 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.
09.01.04 Eltrombopag 
  • Available as tablets
05.03.01 Elvitegravir with cobicistat, emtricitabine and tenofovir alafenamide Genvoya®
  • Available as tablets
  • Manufacturer advises effective contraception in women of childbearing potential; if using a hormonal contraceptive, it must contain drospirenone or norgestimate as the progestogen and at least 30mcg ethinylestradiol.
  • If a dose is more than 18 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.
  • Patients and carers should be counselled on the effects on driving and performance of skilled tasks due to the increased risk of dizziness.
05.03.01 Elvitegravir with cobicistat, emtricitabine and tenofovir disoproxil Stribild®
  • Available as tablets
  • Women of child-bearing potential should use effective contraception during treatment (if using a hormonal contraceptive, it must contain norgestimate as the progestogen and at least 30mcg ethinylestradiol).
  • If a dose is more than 18 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.
06.01.02.03 Empagliflozin Jardiance®
05.03.01 Emtricitabine Emtriva®
  • Available as capsules
  • If a dose is more than 12 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.
05.03.01 Emtricitabine with rilpivirine and tenofovir alafenamide Odefsey®
  • Available as tablets
  • Patients and carers should be counselled on the effects on driving and performance of skilled tasks due to the increased risk of dizziness.
  • If vomiting occurs within 4 hours of taking a dose, a replacement dose should be taken.
05.03.01 Emtricitabine with tenofivir alafenamide Descovy®
  • Available as tablets
  • Patients and carers should be counselled on the effects on driving and performance of skilled tasks due to the increased risk of dizziness.
05.03.01 Emtricitabine with tenofivir disoproxil Truvada®
  • Available as tablets
  • Patients with swallowing difficulties may disperse tablet in half a glass of water, orange juice, or grape juice (but bitter taste).
  • If a dose is more than 12 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.
05.03.01 Emtricitabine, Rilpivirine and Tenofovir  Eviplera®
  • Available as tablets
  • If a dose is more than 12 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.
13.02.01 Emulsifying Ointment BP 
  • £/500g
02.08.01 Enoxaparin Clexane® or Inhixa®
  • Available as injection
    • 20mg/0.2mL ££/10 injections
    • 40mg/0.4mL ££/10 injections
    • 60mg/0.6mL ££/10 injections
    • 80mg/0.8mL £££/10 injections
    • 100mg/1mL £££/10 injections
    • 120mg/0.8mL £££/10 injections
    • 150mg/1mL £££/10 injections
  • Clexane is the brand of choice, Inhixa a biosimilar is used when there are stock shortages of Clexane
04.09.01 Entacapone 
08.03.04.02 Enzalutamide Xtandi®
13.02.01 Epimax Cream 
  • £/500g
  • Alternative to diprobase and oilatum cream
13.02.01 Epimax Ointment 
  • £/500g
08.01.02 Epirubicin hydrochloride 
02.02.03 Eplerenone 
  • Available as tablets 25mg £ & 50mg ££ 
  • Second line agent if Spironlactone not tolerated
02.08.01 Epoprostenol 
  • Available as injection 500mcg ££/1 vial
03.07 Erdosteine Erdotin®
  • Available as capsules £/20
  • Restricted for one named patient only - check with formulary/respiratory pharmacist
09.06.04 Ergocalciferol 
  • Colecalciferol (Vitamin D3) is the preferred choice of vitamin D, however, oral ergocalciferol may be appropriate in vegan patients and IM ergocalciferol when oral absorption is poor
  • Available as:
    • 50000 unit Capsules
    • 300000 unit IM injection
07.01.01 Ergometrine Maleate 
07.01.01 Ergometrine Maleate and Oxytocin Syntometrine®
08.01.06 Eribulin Halaven®

BlueTeq for NICE TA423

05.01.02.02 Ertapenem 
  • Available as injection
  • Please refer to Trust antibiotic guidelines or contact antibiotic pharmacist bleep 5038 for advice
05.01.05 Erythromycin 
  • Available as:
    • Tablets
    • Oral solution
    • Injection Restricted Drug 
10.01.03 Etanercept Benepali® Enbrel®
  • Available as  SC injection
  • Restricted for use in line with NICE TAs below by rheumatology specialist
05.01.09 Ethambutol  
  • Available as tablets
  • Patients who cannot understand warnings about visual side-effects should, if possible, be given an alternative drug. In particular, ethambutol should be used with caution in children until they are at least 5 years old and capable of reporting symptomatic visual changes accurately.
  • Ocular toxicity is more common where excessive dosage is sued or if the patient's renal function is impaired. Early discontinuation of the drug is almost always followed by recover of eyesight.
  • The earliest features of ocular toxicity are subjective and patients should be advised to discontinue therapy immediately if they develop deterioration in vison and promptly seek further advice.
08.03.01 Ethinylestradol 
15.02 Ethyl Chloride Axongesic® Spray
  • Available as spray
15.01.01 Etomidate 
  • Available as 20mg/10ml injection
  • Etomidate should only be administered by, or under the direct supervision of, personnel experienced in its use, with adequate training in anaesthesia and airway management, and when resuscitation equipment is available
08.01.04 Etoposide 
10.01.01 Etoricoxib Arcoxia®
  • Available as tablets
08.01.06 Everolimus Afinitor®

BlueTeq for NICE TA421, TA432 and TA449

02.12 Evolocumab Repatha®
  • Available as injection 140mg/mL £££/2 pens
13.02.01 ExCetra cream 
  • £/500g
  • Similar to Cetraben cream but less expensive
08.03.04.01 Exemestane 
06.01.02.03 Exenatide Byetta®
06.01.02.03 Exenatide prolonged release Bydureon®
02.12 Ezetimibe Ezetrol®
  • Available as tablet £/28
10.01.04 Febuxostat Adenuric®
  • Available as tablets
  • Restricted for use in line with NICE guidance for those with a true allergy to allopurinol
02.12 Fenofibrate 
  • Available as tablets/capsules
15.01.04.03 Fentanyl 
  • Available as injection 0.1mg/2mL
04.07.02 Fentanyl patches 
04.07.02 Fentanyl sublingual tablets Abstral®
  • Palliative care only
09.01.01.02 Ferric Carboxymaltose Ferinject®
  • Available as 100mg, 500mg and 1000mg injection
09.01.01.01 Ferrous fumarate 
  • Available as:
    • Tablets 210mg = 68mg iron
    • Oral solution 140mg/5ml = 45mg iron
09.01.01.01 Ferrous Sulphate 
  • Available as 200mg tablets = 65mg iron
07.04.02 Fesoterodine Toviaz®
  • Third choice if frequency predominates
03.04.01 Fexofenadine 
  • Available as tablets 30mg ££/60, 120mg £/30 & 180mg £/30
05.01.07 Fidaxomicin 
  • Available as tablets
  • Restricted for the treatment of C.difficile as per trust guidelines
09.01.06 Filgrastim Zarzio®
  • Available as injection
06.04.02 Finasteride 
02.03.02 Flecainide 
  • Available as:
    • Tablets 50mg £/60 tablets & 100mg ££/60 tablets
    • Injection  ££/5 ampoules
05.01.01.02 Flucloxacillin 
  • Available as:
    • Capsules
    • Injection
    • Oral solution
05.02.01 Fluconazole 
  • Available as:
    • Capsules
    • Oral solution
    • Injection
07.02.02 Fluconazole 
08.01.03 Fludarabine Phosphate Fludara®
06.03.01 Fludrocortisone 
15.01.07 Flumazenil Anexate®
  • Available as injection
12.01.01 Flumetasone 0.02% with Clioquinol 1% 
  • Available as ear drops 10mL
11.08.02 Fluorescein Sodium 1% & 2% eye drops  Detection of lesions and foreign bodies
11.04.01 Fluorometholone eye drops FML® Not licensed for use in children under 2
08.01.03 Fluorouracil 
04.03.03 Fluoxetine 
  • Available as:
    • Capsules 20mg £/30
    • Oral solution 20mg/5mL £/70mL
03.02 Fluticasone and salmeterol DPI 100/50, 250/50, 500/50 Seretide Accuhaler®
  • Available as 100, 250 & 500 DPI ££/60 dose
03.02 Fluticasone and salmeterol DPI 500/50 AirFluSal Forspiro®
  • Available as DPI ££/60 dose (cheaper than Seretide 500 Accuhaler)
03.02 Fluticasone and salmeterol pMDI 50/25, 125/25, 250/25 Seretide Evohaler®
  • Available as pMDI 50, 125 & 250 ££/120 dose
12.02.01 Fluticasone furoate Avamys®
  • Available as 27.5mcg/dose nasap spray 120 dose
03.02 Fluticasone furoate & vilanterol Relvar Ellipta®
  • Available as 92/22 & 184/22 DPI ££/30 dose
12.02.01 Fluticasone Propionate 
  • Available as 50mcg/dose nasal spray 150 dose
12.02.01 Fluticasone Propionate Flixonase Nasule®
  • Available as  400mcg/unit dose nasal drops 28 unit dose
03.02 Fluticasone with formoterol pMDI 50, 125, 250 Flutiform®
  • Available as 50/5, 125/5, 250/10 pMDI ££/120 dose
09.01.02 Folic Acid 
  • Available as:
    • Tablets (400mcg and 5mg)
    • Oral solution
08.01 Folinic acid (as calcium folinate) 
02.08.01 Fondaparinux 
  • Available as injection
    • 1.5mg/0.3mL £££/10 injections
    • 2.5mg/0.5mL £££/10 injections
    • 7.5mg/0.6mL ££££/10 injections
  • To be used when Enoxaparin unsuitable/not tolerated
03.01.01.01 Formoterol  
  • Available as Easyhaler ££/120 dose
  • Oxis turbohaler is non-formulary - has been ordered in on occasion for patients who have been unable to bring in their own supplies from home
08.03.04.01 Fulvestrant Faslodex®
02.02.02 Furosemide 
  • Available as:
    • Tablet 20mg & 40mg  £ (all strengths)
    • Liquid 40mg/5mL & 50mg/5mL ££ (all strengths)
    • Injection 20mg/2mL £/10 ampoules, 50mg/5mL £/10 ampoules, 250mg/25mL ££/10 ampoules
  • IV doses of 40-80mg can be slow bolused, larger doses must be infused at a max rate of 4mg/min
11.03.01 Fusidic Acid 1% eye drops 
04.07.03 Gabapentin 
04.08.01 Gabapentin 
01.01.02 Gaviscon Infant 
  • Available as sachets £/pack of 15 dual-sachets
  • Each half of the dual-sachet is identified as 'one dose', to avoid errors prescribe with directions in terms of 'dose'
08.01.06 Gefitinib Iressa®
09.02.02.02 Gelatin Gelofusine®
09.02.02.02 Gelatin Gelaspan®
12.03.01 Gelclair® 
  • Available as oral gel
08.01.03 Gemcitabine Gemzar®
07.01.01 Gemeprost 
05.01.04 Gentamicin 
  • Available as injection
12.01.01 Gentamicin Genticin®
  • Available as 0.3% ear/eye drops 10mL
11.03.01 Gentamicin 0.3% eye drops 
12.03.05 Glandosane® 
06.01.02.01 Gliclazide 
06.01.02.01 Gliclazide MR 
  • Not to be used routinely, for use when hypoglycaemia attributed to conventional sulphonylurea
06.01.02.01 Glimepiride 
06.01.04 Glucagon GlucaGen® HypoKit
09.02.02.01 Glucose Intravenous 
  • Available as:
    • Dextrose 5% 50ml bag
    • Dextrose 5% 100ml bag
    • Dextrose 5% 250ml bag
    • Dextrose 5% 500ml bag
    • Dextrose 5% 1000ml bag
    • Dextrose 10% 500ml bag
    • Dextrose 10% 1000ml bag
    • Dextrose 20% 500ml bag
    • Dextrose 50% 500ml bag
06.01.04 Glucose oral gel GlucoGel® GlucoBoost®
01.06.02 Glycerol (Glycerin) 
  • Available as suppositories £/12 suppositories
  • Suppositories should be moistened with water prior to administration
02.06.01 Glyceryl Trinitrate  
  • Available as sublingual spray £/200 dose
02.06.01 Glyceryl Trinitrate  
  • Available as patches 5mg/24 hour & 10mg/24 hour ££/28 patches (both strengths)
  • To be used when the patient is nil by mouth
02.06.01 Glyceryl Trinitrate  
  • Available as injection 5mg/5ml ££/10 ampoules & 50mg/50mL ££/1 vial
01.07.04 Glyceryl Trinitrate 0.4% Rectogesic®
  • Available as ointment ££/30g
07.04.04 Glycine 1.5% bladder irrigation 
03.01.02 Glycopyrronium Seebri breezhaler®
  • Available as 44mcg inhalation powder capsules with device ££/30 capsule pack
15.01.03 Glycopyrronium 
  • Available as:
    • 200mcg/mL injection
    • 600mcg/3mL injection
03.01.04 Glycopyrronium with indacaterol inhaler Ultibro Breezhaler®
  • Available as Ultibro Breezhaler 85mcg/43mcg inhalation powder capsules ££/30 capsule pack
01.05.03 Golimumab Simponi®
  • Available as injection £££££
10.01.03 Golimumab Simponi®
  • Available as  SC injection
  • Restricted for use in line with NICE TAs below by rheumatology specialist
06.07.02 Goserelin Zoladex®
08.03.04.02 Goserelin Zoladex®
08.03.04.02 Goserelin Zoladex® LA
08.03.04.01 Goserelin-Zoladex® 
04.06 Granisetron  
  • Available as:
    • Injection 1mg/1mL ££/5 ampoules
    • Tablets 1mg ££/10
    • Patch 3.1mg/24hours £££/1 patch
09.08.02 Haem Arginate Normasang®
14.04 Haemophilus influenzae type B Combined Vaccine Menitorix®
  • Hib/Men C
  • Given as a single jab at 1 year containing vaccines against meningitis C (first dose) and Hib (fourth dose)
01.07.01 Haemorrhoid relief ointment Anusol®
  • Available as ointment £/25g tube
01.07.01 Haemorrhoid relief suppositories Anusol®
  • Available as suppositories £/12 suppositories
04.02.01 Haloperidol 
  • Available as:
    • 1.5mg & 10mg tablets ££/28 both strengths
    • 0.5mg capsules ££/30
    • 5mg/5mL & 10mg/5mL oral solution ££/100mL both strengths
    • 5mg/1mL injection ££/10 ampoules
02.08.01 Heparin 
  • Available as injection
02.08.01 Heparin 
14.04 Hepatitis A vaccine (monodose) 
14.04 Hepatitis A vaccine with Hepatitis B vaccine  Twinrix®
14.05.02 Hepatitis B immunoglobulin 
  • This should be obtained by contacting UHCW microbiology
14.04 Hepatitis B vaccine Single Component Engerix B®
09.02.02.02 Human Albumin Solution 
  • Available as 5% and 20%
14.04 Human papilloma virus vaccine Gardasil®
02.05.01 Hydralazine 
  • Available as a tablet 25mg & 50mg ££/56 tablets
  • May be used in combination with a nitrate in the management of heart failure in patients who are intolerant of ACE inhibitors
06.03.02 Hydrocortisone 
12.03.01 Hydrocortisone (as sodium succinate) Corlan®
  • Available as 2.5mg muco-adhesive buccal tablet (lozenge)
12.01.01 Hydrocortisone Acetate 1% with Gentamicin 0.3% 
  • Available as ear drops 10mL
  • Gentisone HC brand has been discontinued, now only available as a generic
01.05.02 Hydrocortisone IV 
  • Available as injection £/vial
13.02.01 Hydromol Intensive 10% 
  • £/100g
  • Contains urea
  • Alternative to Calmurid
  • Dermatology only
13.02.01 Hydromol Ointment® 
  • £/500g
13.02.01.01 Hydromol® bath and shower 
  • £/500mL
09.01.02 Hydroxocobalamin 
  • Available as IM injection
  • First choice in treatment of B12 deficiency as it is retained in the body longer than cyanocobalamin
08.01.06 Hydroxycarbamide 
10.01.03 Hydroxychloroquine 
  • Available as tablets
  • Before treatment:
    • assess renal and liver function
    • ask patient about visual impairment (not corrected by glasses), if impairment or eye disorder present, assessment by an optometrist is advised and any abnormality should be referred to an opthalmologist
    • record near visual acuity of each eye (with glasses where appropriate) using a standard reading chart
    • inditiate hydroxychloroquine treatment if no abnormality detected.
  • During treatment:
    • ask patient about visual symptoms and monitor visual acuity annually  using the standard reading chart
    • refer to opthalmologist if visual acuity changes or if vision blurred and warn patient to seek prescribing doctor's advice about stopping treatment
    • if long term treatment is required (more than 5 years). individual arrangment should be agreed with the local opthalmologist
03.04.01 Hydroxyzine 
  • Available as tablets 10mg £/84 & 25mg £/28
01.02 Hyoscine Butylbromide 
  • Available as:
    • Tablets £
    • Injection £/10 ampoule pack
  • Injection cautioned in cardiac disease MHRA advice
  • Be aware of potential for abuse - reports of it being crush and smoked (smoking releases scopolamine a known potent hallucinogenic)
04.06 Hyoscine Hydrobromide 
  • Available as:
    • Tablets 0.3mg £/12
    • Transdermal patch 1.5mg/72 hours ££/2
    • Injection 600mcg/mL £££/10 ampoules
15.01.03 Hyoscine Hydrobromide 
  • Available as:
    • 400mcg/mL
    • 600mcg/mL
03.07 Hypertonic sodium chloride  MucoClear®6%
  • Available as nebuliser solution ££/60 ampoules
11.08.01 Hypromellose 0.3% eye drops 
08.01.06 Ibrutinib Imbruvica®
10.01.01 Ibuprofen 
  • Available as:
    • Tablets
    • Oral solution
    • Topical gel
  • Good first choice NSAID with doses up to 1200mg per day, if higher doses are needed then Naproxen may be a more appropriate choice
  • 2400mg per day is associated with CV risks similar to COX2s and Diclofenac
10.03.02 Ibuprofen gel 
  • 5% gel is first line
  • Systemic side effects are still possible
  • Of use when only one joint is affected and patient unable to tolerate oral NSAIDs
02.08.02 Idarucizumab Praxbind®
  • Available as injection £££££/2 vials
  • Reversal agent for dabigatran
  • ~ £1000 per dose
  • On advice from consultant haematologist
08.01.06 Imatinib Gilvec®
13.02.01 ImuDERM Urea Emollient® 
  • ££/500g
  • Contains urea
02.02.01 Indapamide 
  • Available as:
    • 2.5mg tablet (preferred) £
    • 1.5mg MR tablet £ (but more expensive than standard release)
14.04 Infanrix hexa® 
  • diphtheria/tetanus/5-component acellular pertussis/inactivated polio vaccine/Haemophilus influenzae type b and hepatitis b (DTaP/IPV/Hib/HepB)
  • Replaces Pedicael and Infanrix IPV+ Hib in routine childhood immunisation programme for babies born after 1st August 2017 
  • This is known as the 6-in-1 vaccine and is given at 8,12 and 16 weeks old
01.05.03 Infliximab Remicade®
  • Available as injection ££££
10.01.03 Infliximab Remsima®
  • Available as IV infusion via aseptics
  • Restricted for use in line with NICE TAs below by rheumatology specialist
14.04 Influenza vaccine  
06.01.01.01 Insulin Aspart  NovoRapid®
06.01.01.01 Insulin Aspart Fiasp®
  • Restricted for use in patients who experience mid meal hypoglycaemias who are already on rapid acting analogue insulins for both T1DM and GDM
06.01.01.02 Insulin Degludec Tresiba®
  • Long acting
  • Available as 100unit per 1ml and 200unit per 1ml
06.01.01.02 Insulin Detemir Levemir®
  • Long acting
06.01.01.02 Insulin Glargine Lantus®
  • Long acting
06.01.01.02 Insulin Glargine Toujeo®
  • Long acting
  • Available 300units per 1ml
06.01.01.02 Insulin Glargine Abasaglar®
  • Long acting
06.01.01.01 Insulin Glulisine Apidra®
06.01.01.01 Insulin Human Actrapid®
06.01.01.01 Insulin Human Humulin® S
06.01.01.01 Insulin Human Insuman® Rapid
06.01.01.01 Insulin Lispro Humalog® Humalog ®junior
  • Humalog junior is a device that dials up in increments of 0.5 units
09.03 Intralipid 20% 
06.02.02 Iodide with Iodine 
03.01.02 Ipratropium 
  • Available as:
    • pMDI ££/200 dose
    • nebules 250mcg/mL & 500mcg/2mL £/20
  • Short-acting anti-muscarinic
12.02.02 Ipratropium Bromide Rinatec®
  • Available as 21mcg/dose nasal spray 180 dose
02.05.05.02 Irbesartan 
  • Available as tablets 75mg, 150mg & 300mg £/28 tablets (all strengths)
  • 2nd line agent for Type 2 diabetics who have not tolerated ACEi
08.01.06 Irinotecan Hydrochloride 
09.01.01.02 Iron Isomaltoside Monofer®
  • Available as 500mg and 1000mg injection
15.01.02 Isoflurane 
  • Available as inhalation vapour (250mL bottle)
05.01.09 Isoniazid 
  • Available as tablets
  • Peripheral neuropathy is more likely to occur where there are pre-existing risk factors such as diabetes, alcohol dependence, chronic renal failure, pregnancy, malnutrition and HIV infection. In patients at increased risk of peripheral neuropathy, pyridoxine whould be given prophylactically from the start.
  • Patients/carers should be told how to recognise signs of liver disorder, and advised to discontinue treatment and seek immediate medical attention if symptoms such as persistent nausea, vomiting, malaise or jaundice develop.
06.01.01.02 Isophane Insulin Insulatard®
  • Intermediate acting
06.01.01.02 Isophane Insulin Humulin® I
  • Intermediate acting
02.06.01 Isosorbide Mononitrate 
  • Available as:
    • tablets 10mg & 20mg £/56 tablets
    • MR tablets/capsules (preferred)
  • Short acting preparations should be prescribed asymmetrically to avoid nitrate tolerance
01.06.01 Ispaghula Husk 
  • Available as sachets £/30 sachets
  • Adequate fluid intake is important to avoid obstruction (doses should be taken with at least 150 mL of liquid) and patients should be advised not to take just before bed
  • The fluid is quite thick and should be taken as soon as possible as it will thicken further on standing
  • Time to effect is approximately 48-72 hours
02.06.03 Ivabradine 
  • Available as tablets 5mg ££/56 tablets & 7.5mg £££/56 tablets
  • Manufacturer advises reduce initial dose to 2.5mg twice daily with concurrent use of moderate CYP3A4 inhibitors (except diltiazem, erythromycin and verapamil where concurrent use is contra-indicated)
15.01.01 Ketamine injection Ketalar®
  • Available as 500mg/10mL injection
  • Ketamine should only be administered by, or under the direct supervision of, personnel experienced in its use, with adequate training in anaesthesia and airway management, and when resuscitation equipment is available
15.01.04.02 Ketorolac Toradol®
  • Available as injection 30mg/mL
11.08.02 Ketorolac 0.5% eye drops Acular®
  • PRE-OP ONLY
02.04 Labetalol 
  • Available as:
    • Tablets 100mg £/56 tablets & 200mg ££/56 tablets 
    • Injection 100mg/20mL £££/5 ampoules
04.08.01 Lacosamide 
01.06.04 Lactulose 
  • Available as oral solution £/300mL & 500mL bottle
  • Time to effect approximately up to 48 hours
  • Nausea associated with lactulose can be reduced by adminstration with water, fruit juice of meals
05.03.01 Lamivudine and Dolutegravir Dovato ®
  • Available as tablets
  • Manufacturer recommends Dolutegravir should not be prescribed to women who are trying to become pregnant and should be excluded in women of child bearing potential with pregnancy testing before commencement.
  • Women of child bearing potential should be advised to use effective contraception throughout treatment.
  • If pregnancy is confirmed in the first Trimesterwhilst a woman is taking Dolutegravir, switch to an alternative treatment unless there is no suitable alternative.

 

Two drug regimen and is non inferior to the three drug regimen

Less Renal toxicity

Lower cardiovascular risk

Low resistance

Good Tolerability

Small size tablet for compliance

05.03.01 Lamivudine oral solution Epivir®
  • Lamivudine oral solution is not stocked in pharmacy but can be ordered in for use in neonates (2nd line agent for PEP in neonates as per BHIVA guidelines)
05.03.01 Lamivudine tablets Epivir®
04.08.01 Lamotrigine 
01.03.05 Lansoprazole 
  • Available as capsules £ (all strengths)
01.03.05 Lansoprazole  
  • Available as orodispersible tablet £ (all strengths) - but more expensive than capsules
  • Restricted for those who have swallowing difficulties or have an enteral feeding tube in place
11.06 Latanoprost 0.005% eye drops Xalatan® Monoprost® STEP ONE: Prostaglandin analogues
11.06 Latanoprost 0.005% with Timolol 0.5% Xalacom® STEP THREE: Prostaglandin combination preparations (or STEP TWO at the discretion of the physician)
10.01.03 Leflunomide 
  • Available as tablets
08.02.04 Lenalidomide 
08.01.06 Lenvatinib Kisplyx®
  • For use with everolimus
02.06.02 Lercanidipine 
  • Available as tablets 10mg £
  • 2nd line after amlodipine
06.07.02 Leuprorelin Prostap®
08.03.04.02 Leuprorelin Acetate 3.75mg Prostap® SR
04.08.01 Levetiracetam 
11.06 Levobunolol 0.5% eye drops Betagan® STEP TWO: Beta-blockers
15.02 Levobupivacaine Chirocaine®
  • Available as:
    • 0.25% (2.5mg/1mL) injection
    • 0.5% (5mg/1mL) injection
    • 0.75% (7.5mg/1mL) injection
15.02 Levobupivacaine with Fentanyl 
  • Available as levobupivacaine 0.1% with fentanyl 2mcg/mL 100mL bag - Epidural
04.06 Levomepromazine 
  • Available as:
    • Tablets 25mg ££/84
    • Injection 25mg/1mL ££/10 ampoules
  • For relief of nausea and vomiting in terminal illness
06.02.01 Levothyroxine 
02.03.02 Lidocaine 
  • Available as injection
15.02 Lidocaine 
  • Available as 5% ointment 15g
15.02 Lidocaine 
  • Available as 4% topical solution 25mL
15.02 Lidocaine 
  • Available as 1% & 2% injection
15.02 Lidocaine 
  • Available as 10mg per actuation spray
12.03.01 Lidocaine 10% mouth spray 
  • Available as 10mg/actuation spray 50mL
15.02 Lidocaine 2.5% with Prilocaine 2.5% EMLA®
  • Available as cream 5g and 30g
  • Contraindicated in child less than 37 weeks corrected gestational age
15.02 Lidocaine 5% and Phenylephrine 0.5% 
  • Available as topical solution with nasal applicator
01.07.01 Lidocaine 5% ointment 
  • Available as ointment ££/15g tube
12.03.01 Lidocaine 5% ointment 
  • Available as 5% ointment 15g
12.03.01 Lidocaine and Chlorhexidine Instillagel®
  • Use in the mouth is unlicensed and tastes foul
15.02 Lidocaine with Adrenaline Xylocaine®
  • Available as:
    • lidocaine 1% with adrenaline 1 in 200000 injectin
    • lidocaine 2% with adrenaline 1 in 200000 injection
15.02 Lidocaine with Adrenaline Lignospan®
  • Available as lidocaine 2% with adrenaline 1 in 80000 injection
15.02 Lidocaine2% with Chlorhexidine 0.25% Instillagel®
  • Available as gel 6mL and 11mL
01.06.07 Linaclotide Constella▼®
  • Available as capsules ££
  • Specialist initiated for moderate to severe IBS with constipation in line with the locally agreed pathway for the management of IBS-C, i.e. only for patients who have not responded adequately to all other treatment or who are intolerant to them
  • If patients have not experience improvement in their symptoms after 4 weeks of treatment, the patient should be re-examinded and the benefit and risks of continuint treatment reconsidered in accordance with SmPC
06.01.02.03 Linagliptin 
05.01.07 Linezolid 
  • Available as:
    • Tablets
    • Injection

Severe optic neuropathy may occur rarely, particularly if linezolid is used for longer than 28 days:

  • patients should be warded to report symptoms of visual impairment
  • patients experiencing new visual symptoms should be evaluated promptly, and referred to an opthalmologist if necessary
  • visual function should be monitored regularly if treatment is required for longer than 28 days.

Haematopoietic disorders (including thrombocytopenia, anaemia, leucopenia and pancytopenia) have been reported in patients receiving linezolid. It is recommended that FBC are monitored weekly. Close monitoring is recommended in patients who:

  • receive treatment for more than 10-14 days
  • have pre-existing myelosuppression
  • are receiving drugs that may have adverse effects on haemoglobin, blood counts or platelet funciton
  • have severe renal impairment

If significant myelosuppression occurs, treatment should be stopped unless it is considered essential, in which case intensive monitoring of blood counts and appropriate management should be implemented.

06.02.01 Liothryonine injection 
  • Should only ever be used in patients with hypothyroid coma, it should not be initiated in patients that are NBM unless they are severely deficient i.e. have been NBM > 1 month and are symptomatic
06.02.01 Liothyronine tablets 
  • Should only be initiated by an endocrinologist and used in exceptional circumstances with regular review
13.02.01 Liquid and White Soft Paraffin Ointment  
  • ££/500g
11.08.01 Liquid Paraffin with white soft paraffin and wool alcohols eye ointment Lacri-Lube®
  • LONG-TERM MANUFACTURING PROBLEM - please use Xalin night ointment
06.01.02.03 Liraglutide Victoza®
02.05.05.01 Lisinopril 
  • Available as tablets 2.5mg, 5mg, 10mg & 20mg £/28 tablets (all strengths)
06.01.02.03 Lixisenatide Lyxumia®
01.04.02 Loperamide 
  • Available as:
    • Tablets/Capsules £
    • Oral solution £/100mL bottle
03.04.01 Loratadine 
  • Available as:
    • 10mg tablets £/30
    • 5mg/5mL oral solution £/100mL
04.01.02 Lorazepam 
  • Available as:
    • 1mg tablets £/28
    • 4mg/1mL injection ££/10 ampoules
04.08.02 Lorazepam 
15.01.04.01 Lorazepam 
  • Available as:
    • Injection 4mg/mL
    • Tablets
  • Tablets will dissolve under the tongue if the patients has a sufficiently moist mouth and tablets can be dispersed in water
02.05.05.02 Losartan 
  • Available as tablets 25mg, 50mg & 100mg £/28 tablets (all strengths)
03.01.05 Low range peak flow meter Mini-Wright®
  • £/device
06.01.06 Lucozade® 
05.01.03 Lymecycline Tetralysal® 300
  • Available as capsules
  • For dermatology use
01.06.04 Macrogol Movicol®
  • Available as:
    • Sachets £/30 sachets
    • Paediatric sachets £/30 sachets
  • The contents of each 'full strength' sachet of oral powder to be dissolved in half a glass (approx 125 mL) of water; after reconstitution the solution should be kept in a fridge and discarded if unused after 6 hours
  • The contents of each 'paediatric sachet' to be dissolved in a quarter of a glass (approx 60-65 mL) of water, after reconstitution the solution should be kept in a fridge and discarded if unused after 24 hours.
01.06.05 Macrogols Moviprep®
  • ££/4 sachets
  • Bowel cleansing preparation prior to surgery, surgical procedures or radiological examination not treatments for constipation
  • One pair of sachets (A & B) should be reconstituted in 1 litre of water and taken over 1-2 hours. 1 litre of other clear fluid should also be taken during treatment
  • Solid food should not be taken during treatment until procedure completed
  • Treatment can be stopped if bowel motions become watery and clear 
09.05.01.03 Magnesium Aspartate Magnasparte®
  • Available as oral powder
  • Each sachet contains 10mmol magnesium
09.05.01.03 Magnesium Sulphate 
  • Available as 50% injection
02.02.05 Mannitol 
  • Infusion 10% and 20% £/500mL bag
05.03.01 Maraviroc 

Maraviroc is an antagonist of the CCR5 chemokine receptor.

  • Available as tablets
14.04 Measles, Mumps and Rubella Vaccine, Live (MMR) MMRvaxPro®
  • Vaccine given as a single dose at 1 year then again at approx 3 years and 4 months
01.02 Mebeverine Hydrochloride 
  • Available as tablets (135mg only) £
  • To be taken 30 minutes before meals
08.03.02 Medroxyprogesterone Acetate 
10.01.01 Mefenamic Acid 
  • Available as capsules
  • Restricted for the treatment of dysmenorrhoea & menorrhagia
08.03.02 Megestrol Acetate Megace®
04.01.01 Melatonin 
  • Available as:
    • 2mg capsules ££/60 (unlicensed)
    • 2mg MR tablets ££/30
  • For use in older adults with dementia where alternative hypnotics have failed
08.01.01 Melphalan 
04.11 Memantine  Memantine is a suitable alternative for patients with moderate Alzheimer's disease when acetylcholinesterase inhibitiors (e.g. donepezil) are contra-indicated or are not tolerated.

Memantine is the drug of choice for patietns with severe Alzheimers's disease.
09.06.06 Menadiol Sodium Phosphate 
  • Water soluble preparation of Vitamin K
  • Available as 10mg tablets
14.04 Meningococcal A, C, W135, and Y conjugate vaccine Nimenrix®
14.04 Meningococcal group B Vaccine Bexsero®
14.04 Meningococcal group C conjugate vaccine NeisVac-C®
13.02.01 Menthoderm 
  • ££/500g
15.02 Mepivacaine Scandonest Plain®
  • Available as 3% injection
01.05.03 Mercaptopurine 
  • Available as tablets ££/25 tablets
08.01.03 Mercaptopurine 
05.01.02.02 Meropenem 
  • Available as injection
  • Please refer to Trust antibiotic guidelines or contact antibiotic pharmacist bleep 5038 for advice
01.05.01 Mesalazine Foam Salofalk®
  • Available as 1g/application foam enema £/14 doses
01.05.01 Mesalazine Gastro-resistant tablet Octasa MR®
  • Available as MR gastro-resistant tablets 400mg & 800mg ££/90 tablet pack (all strengths)
  • Formulation and release characteristics of MR mesalazine tablets - Enteric coated with Eudragit S, optimal drug release pH >7, site of drug release is the terminal ileum and colon.
01.05.01 Mesalazine Modified-release granules Pentasa®
  • Available as modified release granules sachets 1g ££/50 sachet pack
  • Granules should be placed on tongue and washed down with water or orange juice without chewing
01.05.01 Mesalazine Modified-release tablet Pentasa®
  • Available as MR tablets 500mg ££/100 tablet pack
  • Tablets may be halved, quartered, or disperesed in water, but should not be chewed.
  • Formulation and release characteristics of MR mesalazine tablets - Ethylcellulose coated microgranules to allow slow continuous release, optimal drug release pH is enteral pH, site of drug release is the duodenum to rectum.
01.05.01 Mesalazine Suppository Pentasa® Salofalk®
  • Available as:
    • Pentasa 1g suppositories ££/28 pack
    • Salofalk 500mg suppositories ££/30 pack
  • Asacol 500mg suppositories have been discontinued
08.01 Mesna 
02.07.02 Metaraminol 
  • Available as injection 10mg/1mL ££/10 ampoules
06.01.02.02 Metformin 
01.05.03 Methotrexate 
  • Available as:
    • Tablets - 2.5mg tablets preferred as per NPSA alert ££/100 tablets
    • S/C injection £/pre-filled pen
  • Specialist only for Crohn's disease (shared care for other indications)
08.01.03 Methotrexate 
10.01.03 Methotrexate 
  • Available as:
    • Tablets 2.5mg only
    • SC injection
02.05.02 Methyldopa 
  • Available as tablet 250mg ££/56 tablets
  • Should only be used for hypertension when other agents have failed or aren't suitable
10.01.02.02 Methylprednisolone Acetate Depo-Medrone® with Lidocaine
  • Available as injection
06.03.02 Methylprednisolone IV 
04.06 Metoclopramide 
  • Available as:
    • Tablets 10mg £/28
    • Injection 10mg/2mL £/10 ampoules
    • Oral solution 5mg/5mL ££/150mL
02.02.01 Metolazone 
  • Available as tablets ££/50 tablets
  • Discontinued on the UK market in 2012 but unlicensed import available for use in secondary care
02.04 Metoprolol 
  • Available as:
    • Tablets 50mg & 100mg £/28 tablets
    • Injection 5mg/5mL ££/5 ampoules
05.01.11 Metronidazole 
  • Available as:
    • Tablets
    • Oral solution
    • Suppositories
    • Injection
  • Oral solution is not suitable for any patients with an enteral tube that does not end in the stomach (NJ/PEJ/PEGJ) - in such instances use tablets which will crush and disperse in water.
07.02.02 Metronidazole Zidoval®
12.03.02 Miconazole Daktarin®
  • Available as 20mg/g oromucosal gel
04.08.02 Midazolam 
15.01.04.01 Midazolam 
  • Available as injection
    • 10mg/2mL (palliative care/EoL)
    • 10mg/5mL
    • 5mg/5mL
  • See Chapter 4 for buccal use in epilepsy
07.01.02 Mifepristone Mifegyne®
07.04.02 Mirabegron Betmiga®
  • Third choice when antimuscarinic drugs are contraindicated/ineffective or have unacceptable side effects
04.03.04 Mirtazapine 
  • Available as orodispersible tablets 15mg, 30mg & 45mg £/30 (all strengths)
07.01.01 Misoprostol 
08.01.02 Mitomycin 
15.01.05 Mivacurium Chloride Mivacron®
  • Available as injection
12.02.01 Mometasone Furoate Nasonex®
  • Available as 50mcg/dose nasal spray 140 dose
03.03.02 Montelukast Singulair®
  • Available as:
    • 10mg tablets £/28
    • 4mg & 5mg chewable tablets £/28
    • 4mg granules £/28 sachets
04.07.02 Morphine 
  • For 12 hour release preparations please prescribe Zomorph® (unless patient is on 5mg in which case please prescribe MST®)
02.05.02 Moxonidine 
  • Available as tablets 200mcg, 300mcg & 400mcg £/28 tablets (all strengths)
  • Should only be used for hypertension when other agents have failed or aren't suitable
09.06.07 Multivitamin preparations 
  • Available as:
    • Tablets
    • Oral drops (Abidec®)
12.02.03 Mupirocin 2% in White Soft Paraffin Bactroban Nasal®
  • Available as nasal ointment
  • For eradication therapy (patients with confirmed MRSA), bactroban nasal ointment is used three times a day in both nostrils for 5 days, with Hydrex as a body wash for 5 days (to be used as a shampoo on days 1 and 3)
08.02.01 Mycophenolate Mofetil 
01.06.06 Naloxegol Moventig®
  • Available as tablets £££
  • Specialist initiation for the treatment of opiod induced constipation in patients whose response to laxatives is inadequate in line with NICE TA345
  • The patient should be stabilised before a prescription is requested by primary care
  • Manufacturer advises reduce initial dose to 12.5mg daily with concurrent use of moderate inhibitors of CYP3A4, increasing to 25mg daily if well tolerated
  • Manufacturer advises tablets can be crushed, mixed with 120 mL of water and taken immediately if patients are unable to swallow tablets whole, the mixture may be administered via a NG tube if required.
15.01.07 Naloxone 
  • Available as injection
10.01.01 Naproxen 
  • Available as tablets
  • Good second line choice after Ibuprofen, may have lower CV risk compared to other NSAIDs and COX2s
02.04 Nebivolol 
  • Available as tablets 5mg £/28 tablets
11.04.02 Neodocromil 2% eye drops Rapitil® Allergic conjunctivitis (seasonal)

Prophylactic action, should therefore be used regularly even when symptoms improve

Maximum 12 weeks duration of treatment
10.02.01 Neostigmine 
  • Available as:
    • Tablets
    • Injection - specialist only
15.01.06 Neostigmine 
  • Available as injection
15.01.06 Neostigmine with Glycopyrronium 
  • Available as injection
05.03.01 Nevirapine oral solution Viramune®
  • Nevirapine oral solution is not stocked in pharmacy but can be ordered in for use in neonates (2nd line agent for PEP in neonates as per BHIVA guidelines)
05.03.01 Nevirapine tablets Viramune®
  • Potentially life-threatening hepatoxicity including fatal fulminant hepatitis reported usually in first 6 weeks; discontinue permanently if abnormalities in LFTs accompanied by hypersensitivity reaction; suspend if severe abnormalities in LFTs but no hypersensitivity reaction - discontinue permanently if significant liver function abnormalities recur; monitor patient closely if mild to moderate abnormalities in LFTS with no hypersensitivity reaction.
  • Rash usually in the first 6 weeks is the most common side effect; incidence reduced if introduced at low dose and dose increased gradually over 14 days. Discontinue permanently if severe rash or if rash is accompanied by blistering, oral lesions, conjunctivitis, facial oedema, general malaise or hypersensitivity reaction. If rash mild or moderate may continue without interruption but dose hould not be increased until rash resolves.
  • Patients or their carers should be told how to recognise hypersensitivity reactions and advised to discontinue treatment and seek immediate medical attention if severe skin reactions or symptoms of hepatitis develop.
  • If a dose is more than 8 hours late with the 'immediate release' preparation or more than 12 hours late with teh 'modified release' preparation, the missed dose hsould not be taken and the next dose should be taken at the usual time.
02.06.03 Nicorandil 
  • Available as tablets 10mg £/60 tablets & 20mg ££/60 tablets
04.10.02 Nicotine inhalation vapour 
  • 15mg strength available  - max 6 cartridges daily
04.10.02 Nicotine transdermal patch 
  • Individuals who smoke more than 10 cigarettes daily should begin with high strength patch (21mg)
  • Individuals who smoke less than 10 cigarettes daily should begin with a medium strength patch (14mg)
02.06.02 Nifedipine 
  • Available as tablets/capsules
  • Contact pharmacy for advice on prescribing most cost-effective brand
07.01.03 Nifedipine 
08.01.06 Nilotinib Tasigna®
02.06.02 Nimodipine 
  • Available as:
    • injection
    • tablets 30mg ££/100 tablets
  • Unlicensed use for chronic fatigue patients approved at GEH for use by endocrine consultants
04.01.01 Nitrazepam 
  • Available as 5mg tablets £/28
  • Long acting - may therefore give rise to residual effects the following day!
05.01.13 Nitrofurantoin  
  • Available as:
    • Modified release capsules (preference)
    • Tablets/Capsules
    • Oral solution
  • Oral solution is very expensive, please crush and disperse the standard release tablets where possible
  • Avoid if patients creatinine clearance is <45ml/min.
08.01.05 Nivolumab Opdivo®
02.07.02 Noradrenaline / Norepinephrine 
  • Available as injection 8mg/8mL £££/10 ampoules
06.04.01.02 Norethisterone 
07.03.02.01 Norethisterone 
08.03.02 Norethisterone 
14.05.01 Normal Immunoglobulin  Intratect® Octagam®
  • Viagam discontinued Jan 19
04.07.03 Nortriptyline  
12.03.02 Nystatin Nystan®
  • Available as 100,000units/ml oral suspension
08.02.03 Obinutuzumab Gazyvaro®
08.02.03 Ofatumumab Arzerra®
11.03.01 Ofloxacin 0.3% eye drops 
12.01.03 Olive Oil Ear Drops 
  • Available as ear drops 10mL
  • The patients should lie with the affected ear uppermost for 5 to 10 minutes after a generous amount of hte softening remedy has ben introduced to the ear. Allow ear drops to warm to room temperature before use
05.03.03.02 Ombitasvir with paritaprevir and ritonavir Viekirax®
  • Available as tablets
  • If a dose is more than 12 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.
01.03.05 Omeprazole 
  • Available as capsules £ (all strengths)
  • Capsules can be opened and the granules within swallowed whole
01.03.05 Omeprazole Losec MUPS®
  • Available as MUPS (dispersible) ££ (all strengths)
  • Restricted for use in paediatric patients
01.03.05 Omeprazole IV 
  • Available as injection ££/5 ampoules
  • IV for suspected or confirmed active GI bleed only
  • IV ranitidine should be used in patients NBM. 
04.06 Ondansetron 
  • Available as:
    • Tablets 4mg ££/30 & 8mg ££/10
    • Injection 4mg/2mL ££/5 ampoules & 8mg/4mL £££/5 ampoules
    • Oral solution 4mg/5mL ££/50mL
    • Orodispersible tablet 4mg ££/10
04.09.01 Opicapone 
09.02.01.02 Oral Rehydration Salts Dioralyte®
  • Available as oral powder
12.03.05 Oralieve® dry mouth moisturising gel 
05.03.04 Oseltamivir Tamiflu®
  • Available as:
    • Capsules (can be opened and dispersed in water)
    • Oral solution
08.01.06 Osimertinib Tagrisso®
08.01.06 Oxaliplatin 
11.07 Oxybuprocaine Hydrochloride 0.4% eye drops Minims®
  • PRE-OP ONLY
07.04.02 Oxybutynin 
04.07.02 Oxycodone 
  • Restricted for use in palliative care/intolerance to morphine/renail impairment
05.01.03 Oxytetracycline 
  • Available as tablets
  • For dermatology use
07.01.01 Oxytocin Syntocinon®
08.01.06 Paclitaxel 
08.01.06 Paclitaxel albumin Abraxane®
08.01.06 Palbociclib Ibrance®
05.03.05 Palivizumab Synagis®
  • Available as injection
  • Restricted for Respiratory Syncytial Virus (RSV) in paediatrics
04.06 Palonosetron with netupitant Akynzeo®
  • Approved at DTC 2018 but not yet being used (May 19)
01.09.04 Pancreatin Creon®
  • Available as capsules (10000, 25000, 40000) ££/100 capsules (all strengths)
08.01.06 Panitumumab Vectibix®
08.01.06 Panobinostat Farydak®
04.07.01 Paracetamol 
  • Available as:
    • Tablets 500mg £/32 & 100
    • Injection 500mg/50mL & 1g/100mL £1/vial both strengths
    • Oral solution 120mg/5mL & 250mg/5mL £/100mL both strengths
    • Suppositories 60mg, 125mg, 240mg & 500mg ££/10 all strengths
    • Soluble tablets 500mg £/60
04.07.01 Paracetamol and codeine Co-codamol® 8/500
04.07.01 Paracetamol and codeine Co-codamol® 30/500
  • Available as:
    • Tablets £/30 & 100
    • Effervescent tablets ££/100
04.07.01 Paracetamol and dihydrocodeine Co-dydramol®
09.03 Parenteral Nutrition (TPN or PN) 
  • Contact Pharmacy Aseptics Unit 3261 for advice
08.01.06 Pazopanib Votrient®
14.04 Pediacel® 
  • diphtheria/tetanus/5-component acellular pertussis/inactivated polio vaccine/Haemophilus influenzae type b (DTap/IPV/Hib)
  • For routine childhood immunisations for babies born before 1st August 2017. Will be replaced by Infanrix Hexa for babies born after this date.
05.03.03.01 Peginterferon alfa Pegasys®
  • Available as injection
08.02.03 Peginterferon Alfa Pegasys®
08.01.03 Pemetrexed Alimta®
08.01.06 Pentostatin Nipent®
01.02 Peppermint Oil Capsules 
  • Available as gastro-resistant capsule ££
01.02 Peppermint water 
  • Avalable as oral solution ££/100mL bottle
01.01.02 Peptac 
  • Available as oral solution £
04.08.01 Perampanel Fycompa
02.05.05.01 Perindopril erbumine 
  • Available as tablets 2mg & 4mg £/28 tablets (all strengths)
08.01.06 Pertuzumab Perjeta®
04.07.02 Pethidine 
04.08.01 Phenobarbital 
04.08.02 Phenobarbital 
05.01.01.01 Phenoxymethylpenicillin 
  • Also know as Penicillin V
  • Available as
    • Tablets
    • Oral solution
11.05 Phenylephrine Hydrochloride 2.5% & 10% eye drops Minims® Phenylephrine Hydrochloride Indication: mydriasis

The use of a drop of topical anaesthetic a few minutes before instillation of phenylephrine is recommended to prevent stinging
04.08.01 Phenytoin 
04.08.02 Phenytoin 
09.05.02.01 Phosphate Polyfusor® 
  • Available as 500ml polyfuser
09.05.02.01 Phosphate supplements Phosphate-Sandoz®
  • Available as effervescent tablets
  • Contains 16.1mmol phosphate, 20.4mmol sodium and 3.1mmol potassium per tablet
01.06.04 Phosphates (Rectal) Cleen® Ready to use Enema
  • Available as ready to use enema £/enema
09.06.06 Phytomenadione Konakion® MM
  • Available as 10mg in 1ml injection
09.06.06 Phytomenadione Konakion® MM Paediatric
  • Available as 2mg in 0.2ml injection
  • Licensed for PO, IV or IM use
01.06.05 Picolax® 
  • £/2 sachets
  • Bowel cleansing preparation prior to surgery, surgical procedures or radiological examination not treatments for constipation
  • One sachet should be reconstituted with 150ml of cold water; patients should be warned that heat is generated during reconstitution and that the solution should be allowed to cool before drinking over 10-20 minutes, drink up to a further 2 pints of water if possible
  • Low residue diet recommended on the day before procedure and copious intake of water or other clear fluids recommended during treatement
11.06 Pilocarpine 1%, 2% & 4% eye drops  RESERVE AGENT

Please note that 4% strength are SPECIALIST ONLY
06.01.02.03 Pioglitazone Actos®
05.01.01.04 Piperacillin and Tazobactam Tazocin®
  • Available as injection
  • Reintroduced to antibiotic guidelines September 2018
08.01.02 Pixantrone 
04.07.04.02 Pizotifen 
14.04 Pneumococcal polysaccharide conjugate vaccine (adsorbed) Prevenar 13®
14.04 Pneumovax® II 
09.02.01.01 Polystyrene Sulphonate Resins Calcium Resonium®
  • Available as powder with 15g scoop
  • To be co-prescribed Lactulose in order to prevent constipation/impaction
11.08.01 Polyvinyl Alcohol 1.4% eye drops Liquifilm Tears®
08.02.04 Pomalidomide Imnovid®
09.02.01.01 Potassium Chloride Slow-K®
  • Available as MR tablet
  • 1 tablet = 8mmol K+
  • Only to be used if Sando-k or Kay-cee-L innapropriate
09.02.01.01 Potassium Chloride Kay-Cee-L®
  • Available as liquid
  • 1mL = 1mmol K+
09.02.01.01 Potassium Chloride Sando-K®
  • Available as effervescent tablets
  • 1 tablet = 12mmol K+
09.02.02.01 Potassium Chloride (STRONG) 1.5g in 10mL  
  • Available as 10ml polyamps
  • To treated as a CONTROLLED DRUG
09.02.02.01 Potassium Chloride and Glucose Intravenous Infusion  
  • Note 0.15% = 20mmol/L and 0.3% = 40mmol/L
  • Available as:
    • Potassium Chloride 0.15% & Dextrose 10% 1000ml bag
    • Potassium Chloride 0.15% & Dextorse 5% 1000ml bag
    • Potassium Chloride 0.3% % Dextrose 5% 1000ml bag
09.02.02.01 Potassium Chloride and Sodium Chloride Intravenous Infusion 
  • Available as:
    • Potassium Chloride 0.3% & Sodium Chloride 0.9% 1000ml bag
09.02.02.01 Potassium Chloride, Sodium Chloride and Glucose Intravenous Infusion 
  • Available as:
    • Potassium Chloride 0.15% & Sodium Chloride 0.18% and Dextrose 4% 1000ml bag
    • Potassium Chloride 0.3% & Sodium Chloride 0.18% and Dextrose 4% 1000ml bag
    • Potassium Chloride 0.15% & Sodium Chloride 0.9% Dextrose 5% 500ml bag
    • Potassium Chloride 0.3% & Sodium Chloride 0.45% and Dextrose 5% 1000ml bag
    • Potassium Chloride 0.3% & Sodium Chloride 0.9% and Dextrose 10% 500ml bag
    • Potassium Chloride 0.15% & Sodium Chloride 0.45% and Dextrose 5% 500ml bag
    • Potassium Chloride 0.15% & Sodium Chloride 0.45% and Dextrose 5% 500ml bag
    • Potassium Chloride 0.15% & Sodium Chloride 0.18% and Dextrose 10%
07.04.03 Potassium Citrate 
  • Available to purchase OTC
11.99.99.99 Povodine-iodine 5% eye drops  Cutaneous peri-ocular and conjunctival antisepsis before ocular surgery
04.09.01 Pramipexole 
02.09 Prasugrel Efient®
  • Available as tablets ££/28
  • For initiation by cardiology team
01.05.02 Prednisolone 
  • Available as:
    • Tablets 5mg (ACTAVIS/TEVA brand are suitable for crushing and dispersing) £/28 tablets
    • Suppositores £££/10 suppositories
    • Foam enema ££££/14 doses
  • 25mg strength tablets are reserved for high dose haematology/oncology patients only £££/28 tablets
06.03.02 Prednisolone 
  • 25mg strength prednisolone will only be dispensed when patients are prescribed large doses (e.g. 100mg) by oncology/haematology
  • ACTAVIS brand will crush and disperse in water and are to be used in place of soluble tablets
12.01.01 Prednisolone 0.5%  Predsol®
  • Available as ear/eye drops 0.5%
11.04.01 Prednisolone 0.5% and 1% eye drops Predsol® Pred Forte® Pred Forte® not licensed for use in children (age range not specified by manufacturer)
04.07.03 Pregabalin 
04.08.01 Pregabalin 
15.02 Prilocaine Hydrochloride 
  • Available as 1% and 2% injection
08.01.06 Procarbazine 
04.06 Prochlorperazine 
  • Available as:
    • Buccal tablet 3mg ££/50
    • Tablets 5mg £/28 & £/84
    • Injection 12.5mg/1mL ££/10 ampoules
01.07.02 Proctosedyl 
  • Available as:
    • Ointment ££/30g
    • Suppositories ££/12 suppositories
  • Contains cinchocaine with hydrocortisone
  • Do not use for longer than 7 days
  • To be used morning and night and after each bowel motion
04.09.02 Procyclidine 
02.03.02 Propafenone 
  • Available as tablets 150mg ££/90 tablets
15.01.01 Propofol 
  • Available as:
    • 1000mg/100mL
    • 200mg/20mL
    • 500mg/50mL
  • Propofol should only be administered by, or under the direct supervision of, personnel experienced in its use, with adequate training in anaesthesia and airway management, and when resuscitation equipment is available
02.04 Propranolol 
  • Available as:
    • Tablets 10mg (28), 40mg (28) & 80mg (56) £ (for all strengths)
    • MR capsule 80mg & 160mg £/28 tablets
    • Injection 1mg/1mL ££/10 ampoules
    • Oral solution 5mg/5mL & 50mg/5mL ££/150mL bottle (both strengths)
04.07.04.02 Propranolol 
06.02.02 Propylthiouracil 
  • When substituting, carbimazole 1mg is considered  equivalent to propylthiouracil 10mg but the dose may need adjusting according to response.
  • Severe hepatic reactions have been reported, including fatal cases and cases requiring liver transplant - discontinue if significant liver enzyme abnormalities develop.
02.08.03 Protamine Sulfate 
  • Available as injection 50mg/5mL ££/10 ampoules
11.07 Proxymetacaine Hydrochloride 0.5% eye drops Minims®
  • PRE-OP ONLY
01.06.07 Prucalopride Resolor ®
  • Available as tablets ££/1mg tablets & £££/3mg
05.01.09 Pyrazinamide 
  • Available as tablets
  • Patients/carers should be told how to recognise signs of liver disorder and advised to discontinue treatment and seek immediate medical attention if symptoms such as persistent nausea, vomiting, malaise or jaundice develop.
10.02.01 Pyridostigmine bromide 
  • Available as tablets
09.06.02 Pyridoxine Hydrochloride 
  • Available as tablets
04.02.01 Quetiapine 
  • Available as:
    • 25mg, 100mg, 150mg & 200mg tablets ££/60 all strengths
    • 50mg £££/60 & 200mg ££££/60 MR tablets
10.02.02 Quinine 
  • Available as tablets (200mg and 300mg quinine sulphate, quinine bisulphate not stocked)
13.02.01 QV cream 
  • ££/500g
  • Dermatology advised only
13.02.01.01 QV Gentle Wash® 
  • £/500mL
  • Dermatology only
13.02.01 QV Intensive Ointment 
  • ££/450g
  • Dermatology advised only
05.03.01 Raltegravir Isentress ®

Raltegravir is a HIV-integrase inhibitor

  • Available as tablets
  • Rash occurs commonly, discontinue if severe rash accompanied by fever, malaise, arthralgia, myalgia, blistering, mouth ulceration, conjunctivitis, angiodema, hepatitis or eosinophilia.
08.01.06 Raltitrexed Tomudex®
02.05.05.01 Ramipril 
  • Available as capsules 1.25mg, 2.5mg, 5mg & 10mg £/28 capsules (all strengths)
01.03.01 Ranitidine 
  • Available as:
    • Tablets £
    • Injection £/5 ampoules
    • Oral solution ££
02.06.03 Ranolazine Ranexa®
  • Available as MR tablets 375mg & 500mg ££/60 tablets (both strengths)
  • Add-on therapy for the treatment of angina who are inadequately controlled or intolerant to first-line antianginal therapies
04.09.01 Rasagiline 
10.01.04 Rasburicase Fastertec®
15.01.04.03 Remifentanil 
  • Available as injection 1mg & 5mg
14.04 Revaxis® 
  • diphtheria/tetanus/inactivated polio vaccine  (Td/IPV)
  • Diphtheria containing vaccine for children over 10 years and adults
05.03.03.02 Ribavirin  
  • Available as tablets
  • Exclude pregnancy before treatment in females of childbearing age. Effective contraception is essential during treatment and for 4 months after treatment in females and for 7 months after treatment in males of childbearing age. Routine monthly pregnancy tests recommended. Condoms must be used if partner of male patient is pregnant (ribavirin excreted in semen). 
05.01.09 Rifabutin Mycobutin®
  • Available as capsules
05.01.09 Rifampicin 
  • Available as:
    • Capsules
    • Oral solution
    • Injection
  • Patients/carers should be advised that rifampicin discolours soft contact lenses.
  • Patients/carers should be told how to recognise signs of liver disorder, and advised to discontinue treatment and seek immediate medical attention if symptoms such as persistant nausea, vomiting, malaise or jaundice develop.
05.01.09 Rifampicin and Isoniazid Rifinah® 300
  • Available as tablets
05.01.09 Rifampicin and Isoniazid Rifinah® 150
  • Available as tablets
05.01.09 Rifampicin and Isoniazid and Pyrazinamide Rifater®
  • Available as tablets
05.01.07 Rifaximin Targaxan®
  • Available as tablets
  • For use in recurrent hepatic encephalopathy as per NICE TA337
05.03.01 Rilpivirine hydrochloride Edurant®
  • Available as tablets
  • If a a dose is more than 12 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.
04.02.01 Risperidone 
  • Available as:
    • Tablets 0.5mg & 1mg £/20 & 2mg £/60
    • Orodispersible tablets 0.5mg & 2mg ££/28
    • Oral solution 1mg/mL £/100mL
05.03.01 Ritonavir Norvir®
  • Available as tablets
08.02.03 Rituximab Truxima® MabThera®
10.01.03 Rituximab (rheumatology) Truxima®
  • Available as IV infusion
  • Restricted for use in line with NICE TAs below by rheumatology specialist
02.08.02 Rivaroxaban Xarelto®
  • Available as tablets 10mg ££/10 tablets, 15mg £££/28 tablets & 20mg £££/28 tablets
  • Indications
    • Stroke prevention in AF (SIDC to be completed and faxed to GP surgery)
    • Treatment and prevention of thromboembolic events (SIDC to be completed and faxed to GP surgery)
    • Prophylaxis of VTE post hip and knee replacement surgery (complete course to be supplied by hospital)
15.01.05 Rocuronium Bromide Esmeron®
  • Available as injection
09.01.04 Romiplostim Nplate®
  • Available as injection
04.09.01 Ropinirole 
15.02 Ropivacaine 0.2% and 10ml of 0.75% in 200ml infusion bag 

At George Eliot Hospital there has been a surge in regional anaesthesia and more and more patients are being offered regional anaesthesia for their procedures. The advantage of procedures being carried out under regional block is that they don’t need to sit in recovery bay and can be discharged faster with a much quicker recovery rate.

 

Ropivacaine offers a faster return of Motor function with effective onset and duration of sensory block. A faster return of motor function will allow patients to mobilise faster therefore leading to a quicker discharge time and will represent a significant cost saving.

 

There are specific orthopaedic procedures such as upper limb trauma cases, where consultant Orthopaedic surgeons are requesting local anaesthesia blocks which provide only sensory analgesia with little or no motor block, this enables surgeons to assess motor power of the upper limbs immediately following surgery.

 

Nerve catheters are now also in use on wards for abdominal surgery and rib fractures and this will allow patients to mobilise faster leading to a quicker recovery time, reduced risk of DVT and shorter hospital stay.

 

George Eliot Hospital NHS Trust are currently in the process of developing a method for undertaking total knee replacement as a day case procedure, Ropivacaine would be most suitable for thi.

 

  1. BMC Anesthesiol. 2019 Jun 29:19(1): 114. Doi 10.1186/s12871-019-0787-6

Continuous Adductor Canal Block used for postoperative pain relief after medial Unicondylar Knee Arthroplasty: a randomised, double blind, placebo controlled trial.

 

  1. J Anaesthesiol Clin Pharmacol. 2019 Jan-Mar:35(1):41-46. doi: 10.4103/joacp.JOACP_70_18.

The estimation of minimum effective volume of 0.5% Ropivacaine in ultrasound-guided interscalene brachial plexus nerve block: A clinical trial.

 

  1. J Clin Diagn Res. 2015 Jan; 9(1): UCO1-UC06. Comparison between Bupivacaine and Ropivacaine in

patients undergoing forearm surgeries under axillary brachial plexus block: A prospective randomised study Anupreet Kaur¹, Raj Bahadur Singh², R.K.Tripathi², and Sanjay Choubey²

02.12 Rosuvastatin 
  • Available as tablets 5mg, 10mg, 20mg, 40mg £/28 all strengths (but more expensive than other two statins on the formulary)!
  • May be considered if other preferred statins are not suitable
14.04 Rotavirus vaccine Rotarix®
04.09.01 Rotigotine 
08.01.06 Ruxolitinib Jakavi®
04.09.01 Safinamide 
03.01.01.01 Salbutamol 
  • Available as inhaler
    • 1st line pMDI + spacer £/200 dose
    • 2nd line CFC breath actuated (Salamol Easibreathe) ££/200 dose
    • 3rd line DPI (Easyhaler) ££/200 dose 
  • Available as nebules 2.5mg/2.5mL & 5mg/2.5mL £/20
03.01.01.01 Salmeterol 
  • Available as:
    • pMDI ££/120 dose
    • DPI ££/60 dose
09.05.01.01 Sandocal-1000® 
  • Available as effervescent tablet
06.01.02.03 Saxagliptin Onglyza®
06.01.02.03 Semaglutide Ozempic®
  • 1st line GLP-1 mimetic if atherosclerotic CVD is absent and a GLP-1 receptor agonist is appropriate

  • 2nd line GLP-1 mimetic if atherosclerotic CVD is present and a GLP-1 receptor agonist is appropriate

01.06.02 Senna 
  • Available as:
    • Tablets £
    • Syrup £
  • Time to effect is approximately 8-12 hours
04.03.03 Sertraline 
  • Available as 50mg & 100mg tablets £/28
  • Sertraline has shown to be safe in patients with unstable angina or who have had a recent myocardial infarction.
15.01.02 Sevoflurane 
  • Available as volatile liquid (250mL bottle)
02.05.01 Sildenafil 
  • Generic sildenafil tablets (unlicensed indication): for dose escalation 25mg-100mg three times daily £/4 tablets (25mg, 50mg & 100mg)
  • As Revatio tablets: for use onlly at licensed dose of 20mg three times daily ££££/90 tablets (20mg)
07.04.05 Sildenafil 
03.09.02 Simple Linctus, BP 
  • £/200mL
03.09.02 Simple Linctus, Paediatric BP 
  • £/200mL
02.12 Simvastatin 
  • Available as tablets 10mg,20mg,40mg,80mg £/28 all strengths
06.01.02.03 Sitagliptin 
09.02.01.03 Sodium Bicarbonate 
  • Available as capsule
09.02.02.01 Sodium Bicarbonate 
  • Available as:
    • Sodium Bicarbonate 1.26% polyfuser
    • Sodium Bicarbonate 4.2% polyfuser
    • Sodium Bicarbonate 8.4% polyfuser
12.01.03 Sodium Bicarbonate 5% ear drops 
  • Available as ear drops 10mL
09.02.01.02 Sodium Chloride Slow Sodium®
  • Available as tablets
07.04.04 Sodium Chloride 0.9% bladder irrigation 
07.04.04 Sodium Chloride 0.9% bladder washout 
09.02.02.01 Sodium Chloride and Glucose Intravenous Infusion 
  • Available as:
    • Sodium Chloride 0.9% & Dextrose 5% 500ml bag
    • Sodium Chloride 0.18% & Dextrose 4% 500ml bag
    • Sodium Chloride 0.18% & Dextrose 4% 1000ml bag
    • Sodium Chloride 0.45% & Dextrose 5% 500ml bag
    • Sodium Chloride 0.18% & Dextrose 10% 500ml bag
09.02.02.01 Sodium Chloride Intravenous 
  • Available as:
    • Sodium Chloride 0.9% 50ml bag
    • Sodium Chloride 0.9% 100ml bag
    • Sodium Chloride 0.9% 250ml bag
    • Sodium Chloride 0.9% 1000ml bag
    • Sodium Chloride 0.9% 1000ml bottle
    • Sodium Chloride 0.9% 3000ml bag
    • Sodium Chloride 0.9% polyfuser
    • Sodium Chloride 0.18% polyfuser
    • Sodium Chloride 1.8% polyfuser
    • Sodium Chloride 2.7% polyfuser
    • Sodium Chloride 0.45% 500ml bag
06.06.02 Sodium Clodronate 
11.04.02 Sodium Cromoglicate 2% eye drops   Allergic conjunctivitis (seasonal)

Prophylactic action, should therefore be used regularly even when symptoms improve

Can be sold to the public (in max. pack size of 10mL) for treatment of acute seasonal and perennial allergic conjunctivitis
09.01.01.01 Sodium Feredetate Sytron®
  • Available as 190mg/5ml oral solution = 27.5mg iron
  • Restricted for paediatric use
05.01.07 Sodium fusidate 
  • Available as tablets
01.06.02 Sodium Picosulfate 
  • Available as oral solution £/100mL bottle
  • Time to effect is approximately 6-12 hours
04.08.01 Sodium Valproate 
05.03.03.02 Sofosbuvir with ledipasvir Harvoni®
  • Available as tablets
  • If vomiting occurs within 5 hours of administration, an additional dose should be taken.
  • If a dose is more than 18 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.
  • Manufacturer advises reduce dose of concurrent H2 receptor antagonist if above a dose comparable famotidine 40mg daily.
  • Manufacturer advises reduce dose of concurrent PPI if above a dose comparable to omeprazole 20mg; take at the same time as sofosbuvir with ledipasvir.
05.03.03.02 Sofosbuvir with velpatasvir Epclusa®
  • Available as tablets
  • If vomiting occurs within 3 hours of administration, an additional dose should be taken.
  • Manufacturer advises reduce dose of concurrent H2-receptor antagonist if above a dose comparable to famotidine 40mg twice daily.
  • Manufacturer advises reduce dose of concurrent PPI if above a dose comparable to omeprazole 20mg; take 4 hours after sofosbuvir with velpatasvir.
07.04.02 Solifenacin Vesicare®
  • Third choice when urgency predominates
06.05.01 Somatropin 
08.01.06 Sorafenib Nexavar®
02.04 Sotalol 
  • Available as tablets 40mg & 80mg £/28 tablets (both strengths)
02.02.03 Spironolactone 
  • Available as:
    • Tablets 25mg, 50mg & 100mg £ (all strengths)
    • Oral solution £££/125mL bottle
03.01.05 Standard range peak flow meter Mini-Wright®
  • £/device
02.10.02 Streptokinase 
07.04.04 SUBY G bladder washout 
15.01.06 Sugammadex Bridion®
  • Available as injection
10.01.03 Sulfasalazine EC Salazopyrin EN-Tabs®
  • Available as EC tablet
04.07.04.01 Sumatriptan 
08.01.06 Sunitinib Sutent®
15.01.05 Suxamethonium Chloride 
  • Available as injection
07.04.05 Tadalafil 
08.03.04.01 Tamoxifen 
07.04.01 Tamsulosin 
04.07.02 Tapentadol 
  • Specialist to complete Specialist Initiated Drug Checklist before GP can continue prescribing
05.01.07 Teicoplanin Targocid®
  • Available as injection
  • To be used only on microbiology advice
04.01.01 Temazepam 
  • Available as 10mg tablets £/28
  • Temezepam is treated as a schedule 2 controlled drug at GEH
15.01.04.01 Temazepam 
  • Available as tablets
08.01.06 Temsirolimus Torisel®
05.03.01 Tenofovir Disproxil Viread®
  • Available as tablets
  • If a dose in more than 12 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.
05.03.01 Tenofovir, Efavirenz and Emtricitabine  Atripla®
  • Available as tablets
  • If a dose is more than 12 hours late, the missed dose should not be taken and the next dose should be taken at the normal time.
03.01.01.01 Terbutaline 
  • Available as:
    • turbohaler ££/120 dose  
    • respules ££/20
07.01.03 Terbutaline 
06.06.01 Teriparatide Forsteo®
01.10 Terlipressin 
  • Available as injection £££/5 vials
  • Dose dependent on body weight
06.05.02 Terlipressin 
06.01.06 Test Strips Multistix 8SG®
06.01.06 Test Strips Combur7®
06.04.02 Testosterone decanoate, isocaproate, phenylpropionate and propionate IM Sustanon 250®
06.04.02 Testosterone topical Testogel®
  • Apply thin layer of gel on clean, dry, healthy skin such as shoulders, arms or abdomen, immediately after sachet is opened. Not to be applied on genital area as high alcohol content may cause local irritation. Allow to dry for 3-5 minutes before dressing. Wash hands with soap and water after applying gel, avoid shower or bath for at lease 6 hours.
06.04.02 Testosterone topical Tostran®
  • Apply gel on clean, dry, intact skin of abdomen or both inner thighs, preferably in the morning. Gently rub in with a finger until dry before dressing. Wash hands with soap and water after applying gel; avoid washing application site for at least 2 hours. Not to be applied on genital area.
06.04.02 Testosterone udecanoate IM Nebido®
14.05.02 Tetanus immunoglobulin 
  • Available as 250 unit solution for injection vials
15.02 Tetracaine (Amethocaine) Ametop®
  • Available as 4% gel
  • Licensed from > 1month old
11.07 Tetracaine Hydrochloride 1% eye drops Minims® Amethocaine Hydrochloride
  • PRE-OP ONLY
06.05.01 Tetracosactide Synacthen®
  • Tetracosactide is an analogue of corticotrophin (ACTH). It is used as a diagnostic test for adrenocortical function. Failure of plasma cortisol to rise after administration indicated adrenocortical insufficiency.
08.02.04 Thalidomide 
03.01.03 Theophylline PRESCRIBE BY BRAND
  • Available as:
    • SLO-PHYLLIN 125mg & 250mg sustained release capsules £/56
    • UNIPHYLLIN 200mg £/56, 300mg £/56 & 400mg ££/56 sustained release tablets
    • NUELIN SA 175mg AND 250mg sustained release tablets ££/60
    • NUELIN 133.3mg in 25mL oral liquid [UNLICENSED] ££/500mL
  • The rate of absorption from modified-release preparations can vary between brands. If a prescription for a modified-release oral theophylline preparation dose not specify a brand name, the pharmacist should contact the prescriber and agree the brand to be dispensed. Additionally, it is essential that a patient discharged from hospital should be maintained on the brand on which that patient was stabilised as an in-patient.

09.06.02 Thiamine Pabrinex®
  • Available as injection
09.06.02 Thiamine 
  • Available as tablets
15.01.01 Thiopental 
  • Available as 500mg injection
06.04.01.01 Tibolone Livial®
02.09 Ticagrelor Brilique®
  • Available as tablets £££/56
  • For initiation by cardiology team
05.01.03 Tigecycline 
  • Available as injection
  • Restricted use - on microbiology advice only.
  • Contraindicated in patients hypersensitive to tetracyclines.
11.06 Timolol 0.25% & 0.5% eye drops  STEP TWO: Beta-blockers
03.01.02 Tiotropium Spiriva® Spiriva Respimat® Braltus®
  • Available as:
    • Spiriva® 18mcg inhalation powder capsules with HandiHaler ££/30 capsule pack
    • Braltus® 10mcg inhalation powder capsules with Zonda inhaler ££/30 capsule pack
    • Respimat 2.5mcg/dose solution for inhalation cartridge with device ££/60 dose
  • Despite different doses; Braltus® and Spiriva® Handihaler and Respimat are clinically equivalent, 10 micrograms of Braltus® is equivalent to 18 micrograms of Spiriva® Handihaler and 5 micrograms of Respimat.
  • Capsules for Spiriva® Handihaler and Braltus® should be used for their intended device only.
  • Spiriva® should be prescribed/endorsed with the type of device intended on the prescription (either HandiHaler or Respimat).
03.01.04 Tiotropium with olodaterol Spiolto Respimat®
  • Available as Spiolto Respimat 2.5mcg/dose / 2.5mcg/dose solution for inhalation cartridge with device ££/60 dose
08.01.06 Tivozanib Fotivda®
05.01.04 Tobramycin 
  • Available as injection
01.05.03 Tofacitinib Xeljanz®

 

 

  • Manufacturer advises reduce dose to 5mg once daily with concurrent use of potent CYP3A4 inhibiitors or drugs which are both moderate CYP3A4 and potent CYP2C19 inhibitors.
  • Manufacturer advises patients should receive all recommended vaccinations before starting treatment; live vaccines should be given at least 2 weeks, but preferably 4 weeks before treatment initiation.
  • Manufacturer advises consideration of antituberculosis therapy prior to initiation of tofacitinib in patients with previously untreated latent TB.
10.01.03 Tofacitinib Xeljanz®
  • Available as tablets
  • Approved for use at GEH in January 2019 in line with NICE TA543 for treating active psoriatic arthritis after inadequate response to DMARDs

 

  • Manufacturer advises reduce dose to 5mg once daily with concurrent use of potent CYP3A4 inhibiitors or drugs which are both moderate CYP3A4 and potent CYP2C19 inhibitors.
  • Manufacturer advises patients should receive all recommended vaccinations before starting treatment; live vaccines should be given at least 2 weeks, but preferably 4 weeks before treatment initiation.
  • Manufacturer advises consideration of antituberculosis therapy prior to initiation of tofacitinib in patients with previously untreated latent TB.
07.04.02 Tolterodine 
06.05.02 Tolvaptan 
07.02.01 Topical Oestrogens (Estradiol) Vagifem®
07.02.01 Topical Oestrogens (Estriol) Ovestin®
04.07.04.02 Topiramate 
04.08.01 Topiramate 
08.01.06 Topotecan 
04.07.02 Tramadol 
02.11 Tranexamic Acid 
  • Available as:
    • tablets ££/60
    • injection ££/10 ampoules
08.01.06 Trastuzumab Herzuma®
  • When prescribing, dispensing or administering, check that this is the correct preparation - trastuzumab emtansine and trastuzumab are NOT interchangeable. 
08.01.06 Trastuzumab emtansine Kadcyla®
  • When prescribing, dispensing or administering, check that this is the correct preparation - trastuzumab emtansine and trastuzumab are NOT interchangeable. 
11.06 Travoprost 40mcg/ml eye drops Travatan® STEP ONE: Prostaglandin analogues
11.06 Travoprost with Timolol DuoTrav® STEP THREE: Prostaglandin combination preparations (or STEP TWO at the discretion of the physician)
10.01.02.02 Triamcinolone Acetonide Adcortyl®
  • Available as injection 10mg/ml
10.01.02.02 Triamcinolone Acetonide Kenalog®
  • Available as injection 40mg/ml
08.01.03 Trifluridine with tipiracil Lonsurf®
05.01.08 Trimethoprim 
  • Available as:
    • Tablets
    • Oral solution
  • 2nd line treatment for UTI
05.01.13 Trimethoprim 

See section 5.1.8

06.07.02 Triptorelin Decaptyl®
08.03.04.02 Triptorelin- Decapeptyl® SR 3mg 
11.05 Tropicamide 0.5% & 1% eye drops  Indication: funduscopy
07.04.02 Trospium 
  • Third choice when oxybutynin intolerance, elderly and confusion likely
03.01.02 Umeclidinium  Incruse Ellipta®
  • Available as 55mcg/dose dry powder inhaler ££/30 dose
03.01.04 Umeclidinium with Vilanterol Anoro Ellipta®
  • Available as Anoro Ellipta 55mcg/dose / 22mcg/dose dry powder inhaler ££/30 dose
02.10.02 Urokinase 
  • Available as injection:
    • 10000 units ££/vial
    • 25000 units ££/vial
    • 100000 units £££/vial
01.09.01 Ursodeoxycholic acid 
  • Available as:
    • Tablets 150mg ££/60 tablets
    • Capsules 250mg ££/60 capsules
    • Suspension ££/250mL
  • For primary biliary cirrhosis & cholestasis of pregnancy
01.05.03 Ustekinumab Stelara®
  • Available as injection £££££
05.03.02.01 Valaciclovir Valtrex®
  • Available as tablets
02.05.05.02 Valsartan 
  • Available as capsules 40mg & 80mg £/28 (both strengths)
02.05.05.02 Valsartan with sacubitril Entresto®
  • Available as tablets 24/26 ££/28 tablets, 49/51 ££/28 tablets & 97/103 £££/56 tablets
  • Entresto® tablets contain valsartan and sacubitril; the proportions are expressed in the form x/y where x and y are the strength in milligrams of valsartan and sacubitril respectively.
  • Valsartan, in this formulation is more bioavailable than other tablet formulations - 26mg, 51mg and 103mg valsartan is equivalent to 40mg, 80mg and 160mg, respectively.
  • Furthermore, note that the 26/24mg, 51/49mg and 103/97mg strengths are sometimes refered to as a total of both drug strengths, that is, 50mg, 100mg and 200mg respectively.
05.01.07 Vancomycin 
  • Available as:
    • Capsules
    • Injection to be used orally
    • Injection
  • For inpatients on oral vancomycin please adminster the injection orally - please see link below for guidance on preparation
14.04 Varicella-zoster vaccine Varilrix®
01.05.03 Vedolizumab 
  • Available as injection £££££
01.05.04 Vedolizumab Entyvio®
08.01.06 Vemurafenib Zelboraf®
08.01.06 Venetoclax Venclyxto
04.03.04 Venlafaxine 
  • Available as:
    • MR capsules 37.5mg ££/28, 75mg & 150mg £/28
    • Tablets 36.5mg & 75mg £/56 (both strengths)
02.06.02 Verapamil 
  • Available as:
    • tablets 40mg (84), 80mg (84) and 120mg (28) £/all strengths 
    • MR tablets 120mg & 240mg ££/both strengths
    • injection (specialist only) 5mg/2mL ££/5 vials
06.01.02.03 Vildagliptin with Metformin Eucreas®
08.01.04 Vinblastine Sulphate 
08.01.04 Vincristine Sulphate 
08.01.04 Vinorelbine 
09.06.07 Vitamin and mineral supplements Forceval Soluble®
09.06.02 Vitamin B Compound Strong 
  • Available as tablets
02.08.02 Warfarin 
  • Available as tablets 1mg & 3mg £/28 tablets (both strengths)
  • At GEH we use only 1mg and 3mg tablets
09.02.02.01 Water for Injection 
  • Available as 5ml, 10ml and 20ml polyamps
12.02.02 Xylometazoline Otrivine®
  • Available as
    • 0.1% ear drops 10mL
    • Child ear drops 10mL
13.02.01 Yellow soft paraffin 
  • £/15g
05.03 Zanamivir 10mg/ml solution for infusion Dectova ®

https://www.gov.uk/government/publications/influenza-treatment-and-prophylaxis-using-anti-viral-agents

Dominant circulating strain has a higher risk of Oseltamivir resistance, eg A(H1N1)pdm09

Complicated Influenza

Consider Zanamivir IV if patients:

- cannot use inhaled Zanamivir

- have severe complicated illness such as multi-organ failure

- note: commence as soon as possible and usually within 6 days

Or

Dominant circulating strain has a lower risk of Oseltamivir resistance, eg A(H1N1)pdm09

Complicated Influenza

Consider switching to Zanamivir if:

- Poor clinical response

-evidence of gastrointestinal dysfunction

-subtype testing confirms a strain with potential Oseltamivir resistance, eg A(H1N1)pdm09

05.03.04 Zanamivir inhalation Relenza®
05.03.01 Zidovudine oral solution Retrovir®
  • Zidovudine oral solution is not stocked in pharmacy but can be ordered in for use in neonates (1st and 2nd line agent for PEP in neonates as per BHIVA guidelines)
04.01.01 Zolpidem 
  • Available as 5mg tablets £/28
04.01.01 Zopiclone 
  • Available as 3.75mg & 7.5mg tablets £/28 both strengths
George Eliot Hospital